

# Josep Tabernero Caturla

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/3590611/josep-tabernero-caturla-publications-by-year.pdf>  
**Version:** 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.  
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

701 papers	64,051 citations	107 h-index	243 g-index
806 ext. papers	76,252 ext. citations	7.7 avg, IF	7.36 L-index

#	Paper	IF	Citations
701	MOUNTAINEER-02: Phase 2/3 study of tucatinib, trastuzumab, ramucirumab, and paclitaxel in previously treated HER2+ gastric or gastroesophageal junction adenocarcinoma. <i>Journal of Clinical Oncology</i> , <b>2022</b> , 40, TPS371-TPS371	2.2	1
700	The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology.. <i>Nature Cancer</i> , <b>2022</b> , 3, 251-261	15.4	3
699	Landscape of , Associated Genomic Alterations, and Interrelation With Immuno-Oncology Biomarkers in -Mutated Cancers.. <i>JCO Precision Oncology</i> , <b>2022</b> , 6, e2100245	3.6	2
698	The Evolving Treatment Landscape in -Mutated Metastatic Colorectal Cancer.. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , <b>2022</b> , 42, 1-10	7.1	1
697	Clinical management of metastatic colorectal cancer in the era of precision medicine.. <i>Ca-A Cancer Journal for Clinicians</i> , <b>2022</b> ,	220.7	8
696	GDF15 Is an Eribulin Response Biomarker also Required for Survival of DTP Breast Cancer Cells. <i>Cancers</i> , <b>2022</b> , 14, 2562	6.6	1
695	The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer.. <i>Nature</i> , <b>2021</b> , 600, 727-730	50.4	36
694	Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the OnCovid retrospective, multicentre registry study. <i>Lancet Oncology, The</i> , <b>2021</b> , 22, 1669-1680	21.7	20
693	The Evolving Role of Consensus Molecular Subtypes: a Step Beyond Inpatient Selection for Treatment of Colorectal Cancer. <i>Current Treatment Options in Oncology</i> , <b>2021</b> , 22, 113	5.4	2
692	Time-Dependent COVID-19 Mortality in Patients With Cancer: An Updated Analysis of the OnCovid Registry. <i>JAMA Oncology</i> , <b>2021</b> ,	13.4	13
691	Emerging biological drugs for the treatment of gastroesophageal adenocarcinoma. <i>Expert Opinion on Emerging Drugs</i> , <b>2021</b> , 1-16	3.7	0
690	A comprehensive overview of tumour deposits in colorectal cancer: Towards a next TNM classification.. <i>Cancer Treatment Reviews</i> , <b>2021</b> , 103, 102325	14.4	1
689	Immune cell profiling of the cerebrospinal fluid enables the characterization of the brain metastasis microenvironment. <i>Nature Communications</i> , <b>2021</b> , 12, 1503	17.4	18
688	Trifluridine/tipiracil in patients with metastatic gastroesophageal junction cancer: a subgroup analysis from the phase 3 TAGS study. <i>Gastric Cancer</i> , <b>2021</b> , 24, 970-977	7.6	0
687	SARS-CoV-2 vaccination and phase 1 cancer clinical trials. <i>Lancet Oncology, The</i> , <b>2021</b> , 22, 298-301	21.7	9
686	Systemic pro-inflammatory response identifies patients with cancer with adverse outcomes from SARS-CoV-2 infection: the OnCovid Inflammatory Score <b>2021</b> , 9,		11
685	The Transcription Factor SLUG Uncouples Pancreatic Cancer Progression from the RAF-MEK1/2-ERK1/2 Pathway. <i>Cancer Research</i> , <b>2021</b> , 81, 3849-3861	10.1	2

684	A CT-based Radiomics Signature Is Associated with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors. <i>Radiology</i> , <b>2021</b> , 299, 109-119	20.5	14
683	Digital Display Precision Predictor: the prototype of a global biomarker model to guide treatments with targeted therapy and predict progression-free survival. <i>Npj Precision Oncology</i> , <b>2021</b> , 5, 33	9.8	2
682	José "Pepe" Baselga, MD, PhD: In Memoriam (1959-2021). <i>Cancer Discovery</i> , <b>2021</b> , 11, 1614-1616	24.4	
681	Precision oncology in metastatic colorectal cancer - from biology to medicine. <i>Nature Reviews Clinical Oncology</i> , <b>2021</b> , 18, 506-525	19.4	27
680	Diagnosis and treatment of hepatocellular carcinoma. Update of the consensus document of the AEEH, AEC, SEOM, SERAM, SERVEI, and SETH. <i>Medicina Clínica</i> , <b>2021</b> , 156, 463.e1-463.e30	1	2
679	MONEO: A phase II study of avelumab (Av) plus FLOT in the peri-operative treatment for patients (pts) with resectable gastric or gastroesophageal junction cancer (GC).. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, TPS4155-TPS4155	2.2	1
678	Pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction (G/GEJ) cancer: Initial findings of the global phase 3 KEYNOTE-811 study.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 4013-4013	2.2	32
677	Diagnosis and treatment of hepatocellular carcinoma. Update of the consensus document of the AEEH, AEC, SEOM, SERAM, SERVEI, and SETH. <i>Medicina Clínica (English Edition)</i> , <b>2021</b> , 156, 463.e1-463.e30	0.3	0
676	MATTERHORN: Efficacy and safety of neoadjuvant-adjuvant durvalumab and FLOT chemotherapy in resectable gastric and gastroesophageal junction cancer: A randomized, double-blind, placebo-controlled, phase 3 study.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, TPS4151-TPS4151	2.2	7
675	Assessment of Pembrolizumab Therapy for the Treatment of Microsatellite Instability-High Gastric or Gastroesophageal Junction Cancer Among Patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Clinical Trials. <i>JAMA Oncology</i> , <b>2021</b> , 7, 895-902	13.4	43
674	Up-to-date role of aflibercept in the treatment of colorectal cancer. <i>Expert Opinion on Biological Therapy</i> , <b>2021</b> , 21, 1315-1324	5.4	1
673	Trifluridine/tipiracil plus bevacizumab for third-line management of metastatic colorectal cancer: SUNLIGHT study design. <i>Future Oncology</i> , <b>2021</b> , 17, 1977-1985	3.6	3
672	Determinants of enhanced vulnerability to coronavirus disease 2019 in UK patients with cancer: a European study. <i>European Journal of Cancer</i> , <b>2021</b> , 150, 190-202	7.5	14
671	First-line pembrolizumab/placebo plus trastuzumab and chemotherapy in HER2-positive advanced gastric cancer: KEYNOTE-811. <i>Future Oncology</i> , <b>2021</b> , 17, 491-501	3.6	43
670	Prognostic variables in low and high risk stage III colon cancers treated in two adjuvant chemotherapy trials. <i>European Journal of Cancer</i> , <b>2021</b> , 144, 101-112	7.5	4
669	Effect of lurbinectedin on the QTc interval in patients with advanced solid tumors: an exposure-response analysis. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2021</b> , 87, 113-124	3.5	1
668	MOUNTAINEER: open-label, phase II study of tucatinib combined with trastuzumab for HER2-positive metastatic colorectal cancer (SGNTUC-017, trial in progress).. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, TPS153-TPS153	2.2	6
667	Efficacy of Pembrolizumab Monotherapy for Advanced Gastric/Gastroesophageal Junction Cancer with Programmed Death Ligand 1 Combined Positive Score ≥ 10. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 1923-1931	12.9	23

666	Specialist palliative and end-of-life care for patients with cancer and SARS-CoV-2 infection: a European perspective. <i>Therapeutic Advances in Medical Oncology</i> , <b>2021</b> , 13, 17588359211042224	5.4	3
665	Combined Analysis of Concordance between Liquid and Tumor Tissue Biopsies for Mutations in Colorectal Cancer with a Single Metastasis Site: The METABEAM Study. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 2515-2522	12.9	11
664	Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated V600E-Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 273-284	2.2	60
663	Clinical development and evaluation of a VEGF-D assay in plasma from patients with metastatic colorectal cancer in the RAISE study. <i>Current Medical Research and Opinion</i> , <b>2021</b> , 37, 1769-1778	2.5	
662	Trifluridine/tipiracil versus placebo for third or later lines of treatment in metastatic gastric cancer: an exploratory subgroup analysis from the TAGS study. <i>ESMO Open</i> , <b>2021</b> , 6, 100200	6	3
661	FRESCO-2: a global Phase III study investigating the efficacy and safety of fruquintinib in metastatic colorectal cancer. <i>Future Oncology</i> , <b>2021</b> , 17, 3151-3162	3.6	1
660	Molecular Subtyping Combined with Biological Pathway Analyses to Study Regorafenib Response in Clinically Relevant Mouse Models of Colorectal Cancer. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 5979-5992	12.9	2
659	Single- and multiple-dose pharmacokinetics, potential for CYP3A inhibition, and food effect in patients with cancer and healthy subjects receiving ipatasertib. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2021</b> , 88, 921-930	3.5	1
658	High mRNA Expression Levels Correlate with Response to Selective FGFR Inhibitors in Breast Cancer. <i>Clinical Cancer Research</i> , <b>2021</b> ,	12.9	1
657	The Porto European Cancer Research Summit 2021. <i>Molecular Oncology</i> , <b>2021</b> , 15, 2507-2543	7.9	1
656	Phase I prognostic online (PIPO): A web tool to improve patient selection for oncology early phase clinical trials. <i>European Journal of Cancer</i> , <b>2021</b> , 155, 168-178	7.5	
655	and inhibition as treatment strategies in V600E metastatic colorectal cancer. <i>Therapeutic Advances in Medical Oncology</i> , <b>2021</b> , 13, 1758835921992974	5.4	5
654	Management of adverse events from the treatment of encorafenib plus cetuximab for patients with BRAF V600E-mutant metastatic colorectal cancer: insights from the BEACON CRC study.. <i>ESMO Open</i> , <b>2021</b> , 6, 100328	6	2
653	The Effective Targeting of KRAS Elusiveness. <i>Cancer Cell</i> , <b>2020</b> , 38, 785-787	24.3	2
652	Association of Bevacizumab Plus Oxaliplatin-Based Chemotherapy With Disease-Free Survival and Overall Survival in Patients With Stage II Colon Cancer: A Secondary Analysis of the AVANT Trial. <i>JAMA Network Open</i> , <b>2020</b> , 3, e2020425	10.4	5
651	Evolving Landscape of Molecular Prescreening Strategies for Oncology Early Clinical Trials. <i>JCO Precision Oncology</i> , <b>2020</b> , 4,	3.6	4
650	Incorporating traditional and emerging biomarkers in the clinical management of metastatic colorectal cancer: an update. <i>Expert Review of Molecular Diagnostics</i> , <b>2020</b> , 20, 653-664	3.8	0
649	Clinical Outcomes in Patients With Colon Cancer With Microsatellite Instability of Sporadic or Familial Origin Treated With Adjuvant FOLFOX With or Without Cetuximab: A Pooled Analysis of the PETACC8 and N0147 Trials. <i>JCO Precision Oncology</i> , <b>2020</b> , 4,	3.6	4

648	Health-related quality of life associated with trifluridine/tipiracil in heavily pretreated metastatic gastric cancer: results from TAGS. <i>Gastric Cancer</i> , <b>2020</b> , 23, 689-698	7.6	9
647	Nomogram for Estimating Overall Survival in Patients With Metastatic Pancreatic Cancer. <i>Pancreas</i> , <b>2020</b> , 49, 744-750	2.6	3
646	Support systems to guide clinical decision-making in precision oncology: The Cancer Core Europe Molecular Tumor Board Portal. <i>Nature Medicine</i> , <b>2020</b> , 26, 992-994	50.5	19
645	Design and Conduct of Early Clinical Studies of Immunotherapy: Recommendations from the Task Force on Methodology for the Development of Innovative Cancer Therapies 2019 (MDICT). <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 2461-2465	12.9	2
644	-Mutant Transcriptional Subtypes Predict Outcome of Combined BRAF, MEK, and EGFR Blockade with Dabrafenib, Trametinib, and Panitumumab in Patients with Colorectal Cancer. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 2466-2476	12.9	19
643	Enhancing global access to cancer medicines. <i>Ca-A Cancer Journal for Clinicians</i> , <b>2020</b> , 70, 105-124	220.7	63
642	Final results from the phase I study expansion cohort of the selective FGFR inhibitor Debio 1,347 in patients with solid tumors harboring an FGFR gene fusion.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 3603-3603	2.2	12
641	Encorafenib plus cetuximab with or without binimetinib for BRAF V600E metastatic colorectal cancer: Updated survival results from a randomized, three-arm, phase III study versus choice of either irinotecan or FOLFIRI plus cetuximab (BEACON CRC).. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 4001-4001	2.2	22
640	Encorafenib plus cetuximab with or without binimetinib for BRAF V600E-mutant metastatic colorectal cancer: Quality-of-life results from a randomized, three-arm, phase III study versus the choice of either irinotecan or FOLFIRI plus cetuximab (BEACON CRC).. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 4039-4039	2.2	5
639	Phase III APACT trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P + Gem) versus gemcitabine (Gem) alone for patients with resected pancreatic cancer (PC): Outcomes by geographic region.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 4515-4515	2.2	5
638	Concordance between independent and investigator assessment of disease-free survival (DFS) in the APACT trial.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 4618-4618	2.2	1
637	A phase II basket study of MCLA-128, a bispecific antibody targeting the HER3 pathway, in NRG1 fusion-positive advanced solid tumors.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, TPS3654-TPS3654	2.2	3
636	The PEGASUS trial: Post-surgical liquid biopsy-guided treatment of stage III and high-risk stage II colon cancer patients.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, TPS4124-TPS4124	2.2	6
635	Patient and tumor characteristics as determinants of overall survival (OS) in BRAF V600 mutant (mt) metastatic colorectal cancer (mCRC) treated with doublet or triplet targeted therapy.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 4112-4112	2.2	1
634	The predictive role of plasma mutant allele fraction to antiangiogenic drugs in patients with mCRC: An expanded analysis of surrogate biomarkers of response to first-line treatment with bevacizumab.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 3541-3541	2.2	
633	Survival outcomes among older adults (OA) receiving second-line therapy for metastatic CRC (mCRC): 5,289 patients (pts) from the ARCAD Clinical Trials Program.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 7009-7009	2.2	
632	Epigenetic Gene Repression Confers Sensitivity to Therapeutic BRAFV600E Blockade in Colon Neuroendocrine Carcinomas. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 902-909	12.9	13
631	Population pharmacokinetics and covariate analysis of Sym004, an antibody mixture against the epidermal growth factor receptor, in subjects with metastatic colorectal cancer and other solid tumors. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , <b>2020</b> , 47, 5-18	2.7	0

630	Capturing Hyperprogressive Disease with Immune-Checkpoint Inhibitors Using RECIST 1.1 Criteria. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 1846-1855	12.9	35
629	Impact of Prior Bevacizumab Treatment on VEGF-A and PlGF Levels and Outcome Following Second-Line Aflibercept Treatment: Biomarker Analysis of the VELOUR Trial. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 717-725	12.9	18
628	AXL is a predictor of poor survival and of resistance to anti-EGFR therapy in RAS wild-type metastatic colorectal cancer. <i>European Journal of Cancer</i> , <b>2020</b> , 138, 1-10	7.5	9
627	Clinical portrait of the SARS-CoV-2 epidemic in European cancer patients. <i>Cancer Discovery</i> , <b>2020</b> ,	24.4	96
626	Molecular subtypes and the evolution of treatment management in metastatic colorectal cancer. <i>Therapeutic Advances in Medical Oncology</i> , <b>2020</b> , 12, 1758835920936089	5.4	16
625	Towards a cancer mission in Horizon Europe: recommendations. <i>Molecular Oncology</i> , <b>2020</b> , 14, 1589-1615	5.9	15
624	Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial. <i>JAMA Oncology</i> , <b>2020</b> , 6, 1571-1580	13.4	196
623	Effect of trifluridine/tipiracil in patients treated in RECOURSE by prognostic factors at baseline: an exploratory analysis. <i>ESMO Open</i> , <b>2020</b> , 5,	6	5
622	Identification of Expression Profiles Defining Distinct Prognostic Subsets of Radioactive-Iodine Refractory Differentiated Thyroid Cancer from the DECISION Trial. <i>Molecular Cancer Therapeutics</i> , <b>2020</b> , 19, 312-317	6.1	6
621	Efficacy and Safety of Trifluridine/Tipiracil Treatment in Patients With Metastatic Gastric Cancer Who Had Undergone Gastrectomy: Subgroup Analyses of a Randomized Clinical Trial. <i>JAMA Oncology</i> , <b>2020</b> , 6, e193531	13.4	7
620	The role of PIGF blockade in the treatment of colorectal cancer: overcoming the pitfalls. <i>Expert Opinion on Biological Therapy</i> , <b>2020</b> , 20, 15-22	5.4	10
619	Caring for patients with cancer in the COVID-19 era. <i>Nature Medicine</i> , <b>2020</b> , 26, 665-671	50.5	201
618	Population pharmacokinetics and exposure-overall survival analysis of the transforming growth factor- $\beta$ inhibitor galunisertib in patients with pancreatic cancer. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2019</b> , 84, 1003-1015	3.5	8
617	Targeted multiplex proteomics for molecular prescreening and biomarker discovery in metastatic colorectal cancer. <i>Scientific Reports</i> , <b>2019</b> , 9, 13568	4.9	11
616	Encorafenib, Binimetinib, and Cetuximab in V600E-Mutated Colorectal Cancer. <i>New England Journal of Medicine</i> , <b>2019</b> , 381, 1632-1643	59.2	481
615	- and -Mutated Chemotherapy and Anti-EGFR-Refractory Colorectal Cancer: Should Clonality Guide Target Prioritization With Investigational Therapies?. <i>JCO Precision Oncology</i> , <b>2019</b> , 3, 1-3	3.6	1
614	Cancer Core Europe: A translational research infrastructure for a European mission on cancer. <i>Molecular Oncology</i> , <b>2019</b> , 13, 521-527	7.9	22
613	Ultra-selection of metastatic colorectal cancer patients using next-generation sequencing to improve clinical efficacy of anti-EGFR therapy. <i>Annals of Oncology</i> , <b>2019</b> , 30, 439-446	10.3	14



612	LIF regulates CXCL9 in tumor-associated macrophages and prevents CD8 T cell tumor-infiltration impairing anti-PD1 therapy. <i>Nature Communications</i> , <b>2019</b> , 10, 2416	17.4	64
611	Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 4888-4897	12.9	110
610	Shortages of inexpensive essential medicines. <i>Lancet Oncology, The</i> , <b>2019</b> , 20, e224-e225	21.7	3
609	Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial. <i>Nature Medicine</i> , <b>2019</b> , 25, 751-758	50.5	205
608	Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial. <i>Lancet Oncology, The</i> , <b>2019</b> , 20, 849-861	21.7	201
607	Knowledge and use of biosimilars in oncology: a survey by the European Society for Medical Oncology. <i>ESMO Open</i> , <b>2019</b> , 4, e000460	6	29
606	Phase I dose-escalation of trifluridine/tipiracil in combination with oxaliplatin in patients with metastatic colorectal cancer. <i>European Journal of Cancer</i> , <b>2019</b> , 112, 12-19	7.5	5
605	TGF $\beta$ receptor inhibitor galunisertib is linked to inflammation- and remodeling-related proteins in patients with pancreatic cancer. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2019</b> , 83, 975-991	3.5	36
604	Triple-drug chemotherapy regimens in combination with an anti-EGFR agent in metastatic colorectal cancer - prospects from phase II clinical trials. <i>Expert Opinion on Investigational Drugs</i> , <b>2019</b> , 28, 463-471	5.9	6
603	Comparative Assessment of Clinical Benefit Using the ESMO-Magnitude of Clinical Benefit Scale Version 1.1 and the ASCO Value Framework Net Health Benefit Score. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 336-349	2.2	66
602	ESMO-MCBS: setting the record straight. <i>Lancet Oncology, The</i> , <b>2019</b> , 20, e192	21.7	1
601	Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With V600E-Mutant Metastatic Colorectal Cancer: Safety Lead-In Results From the Phase III BEACON Colorectal Cancer Study. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 1460-1469	2.2	114
600	New clinical trial designs in the era of precision medicine. <i>Molecular Oncology</i> , <b>2019</b> , 13, 549-557	7.9	57
599	Fibroblast Growth Factor Receptor Inhibitors: Enhancing Therapeutic Strategies for Solid Tumors <b>2019</b> , 101-121		
598	Impact of circulating tumor DNA mutant allele fraction on prognosis in RAS-mutant metastatic colorectal cancer. <i>Molecular Oncology</i> , <b>2019</b> , 13, 1827-1835	7.9	21
597	Association of post-operative CEA with survival and oxaliplatin benefit in patients with stage II colon cancer: a post hoc analysis of the MOSAIC trial. <i>British Journal of Cancer</i> , <b>2019</b> , 121, 312-317	8.7	10
596	A phase 2 study of panitumumab with irinotecan as salvage therapy in chemorefractory KRAS exon 2 wild-type metastatic colorectal cancer patients. <i>British Journal of Cancer</i> , <b>2019</b> , 121, 378-383	8.7	2
595	Carcinoembryonic Antigen Levels and Survival in Stage III Colon Cancer: Analysis of the MOSAIC and PETACC-8 Trials. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2019</b> , 28, 1153-1161	4	7

594	Analysis of symptoms and functional HRQoL scales in TAGS, a phase III trial of trifluridine/tipiracil (FTD/TPI) in metastatic gastric cancer (mGC).. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 4043-4043	2.2	3
593	KEYNOTE-811 pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction cancer (mG/GEJC): A double-blind, randomized, placebo-controlled phase 3 study.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, TPS4146-TPS4146	2.2	13
592	BMS-986205, an indoleamine 2, 3-dioxygenase 1 inhibitor (IDO1i), in combination with nivolumab (nivo): Updated safety across all tumor cohorts and efficacy in advanced bladder cancer (advBC).. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 358-358	2.2	22
591	3-month versus 6-month adjuvant chemotherapy for patients with high-risk stage II and III colorectal cancer: 3-year follow-up of the SCOT non-inferiority RCT. <i>Health Technology Assessment</i> , <b>2019</b> , 23, 1-88	4.4	13
590	Phase III randomized sequential open-label study to evaluate the efficacy of FOLFOX + panitumumab followed by FOLFIRI + bevacizumab (Sequence 1) versus FOLFOX+ bevacizumab followed by FOLFIRI + panitumumab (Sequence 2) in untreated patients with wild-type RAS metastatic primary left (L)-sided unresectable colorectal cancer (CRC): The CR-SEQUENCE-1 <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 4005-4014	2.2	1
589	A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring Gene Alterations. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 2699-2707	12.9	66
588	CanStem111P trial: a Phase III study of napabucasin plus nab-paclitaxel with gemcitabine. <i>Future Oncology</i> , <b>2019</b> , 15, 1295-1302	3.6	17
587	KEYNOTE-585: Phase III study of perioperative chemotherapy with or without pembrolizumab for gastric cancer. <i>Future Oncology</i> , <b>2019</b> , 15, 943-952	3.6	59
586	Educational needs in gastrointestinal cancer: a consensus position paper from the ESMO Gastrointestinal Cancer Faculty. <i>ESMO Open</i> , <b>2019</b> , 4, e000533	6	
585	How I treat gastric adenocarcinoma. <i>ESMO Open</i> , <b>2019</b> , 4, e000521	6	10
584	Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic oesophageal cancer: a JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS. <i>Annals of Oncology</i> , <b>2019</b> , 30, 34-43	10.3	48
583	First-in-human phase I study of the microtubule inhibitor plocabulin in patients with advanced solid tumors. <i>Investigational New Drugs</i> , <b>2019</b> , 37, 674-683	4.3	11
582	Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic gastric cancer: a JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS. <i>Annals of Oncology</i> , <b>2019</b> , 30, 19-33	10.3	101
581	Biomarker analysis beyond angiogenesis: RAS/RAF mutation status, tumour sidedness, and second-line ramucirumab efficacy in patients with metastatic colorectal carcinoma from RAISE-a global phase III study. <i>Annals of Oncology</i> , <b>2019</b> , 30, 124-131	10.3	29
580	Global cancer control: responding to the growing burden, rising costs and inequalities in access. <i>ESMO Open</i> , <b>2018</b> , 3, e000285	6	98
579	Phase II Study of the Dual EGFR/HER3 Inhibitor Duligotuzumab (MEHD7945A) versus Cetuximab in Combination with FOLFIRI in Second-Line Wild-Type Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 2276-2284	12.9	25
578	Reply to the letter to the editor 'ESMO-MCBS v1.1: statistical and patient relevant shortcomings' by Emprechtinger et al. <i>Annals of Oncology</i> , <b>2018</b> , 29, 1335-1338	10.3	
577	MODUL-a multicenter randomized clinical trial of biomarker-driven maintenance therapy following first-line standard induction treatment of metastatic colorectal cancer: an adaptable signal-seeking approach. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>2018</b> , 144, 1197-1204	4.9	11



576	Molecular Diagnosis of Diffuse Gliomas through Sequencing of Cell-Free Circulating Tumor DNA from Cerebrospinal Fluid. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 2812-2819	12.9	74
575	Reply to the letter to the editor 'Re-aligning the ASCO and ESMO clinical benefit frameworks or modern cancer therapies'. <i>Annals of Oncology</i> , <b>2018</b> , 29, 774-775	10.3	1
574	Early evolutionary divergence between papillary and anaplastic thyroid cancers. <i>Annals of Oncology</i> , <b>2018</b> , 29, 1454-1460	10.3	30
573	Reply to the letter to the editor 'Toxicity adjustment in the ESMO-MCBS: a Gestalt approach?' by Del Paggio. <i>Annals of Oncology</i> , <b>2018</b> , 29, 521-522	10.3	
572	Combined BRAF, EGFR, and MEK Inhibition in Patients with -Mutant Colorectal Cancer. <i>Cancer Discovery</i> , <b>2018</b> , 8, 428-443	24.4	296
571	Efficacy of Sym004 in Patients With Metastatic Colorectal Cancer With Acquired Resistance to Anti-EGFR Therapy and Molecularly Selected by Circulating Tumor DNA Analyses: A Phase 2 Randomized Clinical Trial. <i>JAMA Oncology</i> , <b>2018</b> , 4, e175245	13.4	54
570	Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO-ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS. <i>Annals of Oncology</i> , <b>2018</b> , 29, 44-70	10.3	260
569	Analysis of angiogenesis biomarkers for ramucirumab efficacy in patients with metastatic colorectal cancer from RAISE, a global, randomized, double-blind, phase III study. <i>Annals of Oncology</i> , <b>2018</b> , 29, 602-609	10.3	61
568	Association of baseline absolute neutrophil counts and survival in patients with metastatic colorectal cancer treated with second-line antiangiogenic therapies: exploratory analyses of the RAISE trial and validation in an electronic medical record data set. <i>ESMO Open</i> , <b>2018</b> , 3, e000347	6	13
567	Cancer Genome Interpreter annotates the biological and clinical relevance of tumor alterations. <i>Genome Medicine</i> , <b>2018</b> , 10, 25	14.4	205
566	Evaluating trifluridine + tipiracil hydrochloride in a fixed combination (TAS-102) for the treatment of colorectal cancer. <i>Expert Opinion on Pharmacotherapy</i> , <b>2018</b> , 19, 623-629	4	4
565	3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial. <i>Lancet Oncology</i> , <b>2018</b> , 19, 562-578	21.7	93
564	RE: Magnitude of Clinical Benefit of Cancer Drugs Approved by the US Food and Drug Administration. <i>Journal of the National Cancer Institute</i> , <b>2018</b> , 110, 1142-1143	9.7	1
563	Effect of Primary Tumor Location on Second- or Later-line Treatment Outcomes in Patients With RAS Wild-type Metastatic Colorectal Cancer and All Treatment Lines in Patients With RAS Mutations in Four Randomized Panitumumab Studies. <i>Clinical Colorectal Cancer</i> , <b>2018</b> , 17, 170-178.e3	3.8	31
562	Dynamic molecular analysis and clinical correlates of tumor evolution within a phase II trial of panitumumab-based therapy in metastatic colorectal cancer. <i>Annals of Oncology</i> , <b>2018</b> , 29, 119-126	10.3	46
561	Age does not influence efficacy of ramucirumab in advanced gastric cancer: Subgroup analyses of REGARD and RAINBOW. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2018</b> , 33, 814-824	4	14
560	Role of Deficient DNA Mismatch Repair Status in Patients With Stage III Colon Cancer Treated With FOLFOX Adjuvant Chemotherapy: A Pooled Analysis From 2 Randomized Clinical Trials. <i>JAMA Oncology</i> , <b>2018</b> , 4, 379-383	13.4	64
559	Prognostic Value of Methylator Phenotype in Stage III Colon Cancer Treated with Oxaliplatin-based Adjuvant Chemotherapy. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 4745-4753	12.9	14

558	The safety of ramucirumab for the treatment of colorectal cancer. <i>Expert Opinion on Drug Safety</i> , <b>2018</b> , 17, 945-951	4.1	9
557	Extracellular HMGA1 Promotes Tumor Invasion and Metastasis in Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 6367-6382	12.9	27
556	TET2 controls chemoresistant slow-cycling cancer cell survival and tumor recurrence. <i>Journal of Clinical Investigation</i> , <b>2018</b> , 128, 3887-3905	15.9	41
555	PK/PD properties of BI 836880, a vascular endothelial growth factor (VEGF)/angiopoietin-2 (Ang-2)-blocking nanobody, in patients (pts) with advanced/metastatic solid tumors.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 2523-2523	2.2	1
554	Pharmacokinetic (PK) and exposure-response (ER) analysis of pertuzumab (P) in patients (pts) with HER2-positive metastatic gastroesophageal junction and gastric cancer (mGEJC/GC).. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 2564-2564	2.2	1
553	A phase I, open-label dose-escalation trial of weekly (qw) BI 836880, a vascular endothelial growth factor (VEGF)/angiopoietin-2 (Ang-2)-blocking Nanobody, in patients (pts) with advanced/metastatic solid tumors.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, e24013-e24013	2.2	1
552	KEYNOTE-585: Phase 3 study of chemotherapy (chemo) + pembrolizumab (pembro) vs chemo + placebo as neoadjuvant/adjuvant treatment for patients (pts) with gastric or gastroesophageal junction (G/GEJ) cancer.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, TPS4136-TPS4136	2.2	3
551	BEACON CRC study safety lead-in (SLI) in patients with BRAFV600E metastatic colorectal cancer (mCRC): Efficacy and tumor markers.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 627-627	2.2	28
550	Medical Oncology Management of Hereditary Colorectal Cancer <b>2018</b> , 401-413		
549	Association of postoperative carcinoembryonic antigen (CEA) levels with survival in stage III colon cancer (CC): Post hoc analysis of the MOSAIC and PETACC-8 studies.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 3568-3568	2.2	
548	Colorectal Cancer Consensus Molecular Subtypes Translated to Preclinical Models Uncover Potentially Targetable Cancer Cell Dependencies. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 794-806	12.9	116
547	Association of Prognostic Value of Primary Tumor Location in Stage III Colon Cancer With RAS and BRAF Mutational Status. <i>JAMA Oncology</i> , <b>2018</b> , 4, e173695	13.4	37
546	A phase II Study Evaluating Combined Neoadjuvant Cetuximab and Chemotherapy Followed by Chemoradiotherapy and Concomitant Cetuximab in Locoregional Oesophageal Cancer Patients. <i>Targeted Oncology</i> , <b>2018</b> , 13, 69-78	5	
545	Molecular Subtypes and the Evolution of Treatment Decisions in Metastatic Colorectal Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , <b>2018</b> , 38, 231-238	7.1	25
544	Reply to M. Mo et al. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 303	2.2	1
543	Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 850-858	2.2	184
542	Phosphatidylinositol 3-Kinase $\alpha$ -Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 1291-1299	2.2	190
541	Biosimilars in oncology. <i>ESMO Open</i> , <b>2018</b> , 3, e000456	6	1

540	Vemurafenib in Patients With Relapsed Refractory Multiple Myeloma Harboring Mutations: A Cohort of the Histology-Independent VE-BASKET Study. <i>JCO Precision Oncology</i> , <b>2018</b> , 2,	3.6	14
539	Prospective multicenter real-world RAS mutation comparison between OncoBEAM-based liquid biopsy and tissue analysis in metastatic colorectal cancer. <i>British Journal of Cancer</i> , <b>2018</b> , 119, 1464-1470	8.7	40
538	SCOT: a comparison of cost-effectiveness from a large randomised phase III trial of two durations of adjuvant Oxaliplatin combination chemotherapy for colorectal cancer. <i>British Journal of Cancer</i> , <b>2018</b> , 119, 1332-1338	8.7	9
537	A slow-cycling LGR5 tumour population mediates basal cell carcinoma relapse after therapy. <i>Nature</i> , <b>2018</b> , 562, 434-438	50.4	68
536	p95HER2-T cell bispecific antibody for breast cancer treatment. <i>Science Translational Medicine</i> , <b>2018</b> , 10,	17.5	40
535	Starting the fight in the tumor: expert recommendations for the development of human intratumoral immunotherapy (HIT-IT). <i>Annals of Oncology</i> , <b>2018</b> , 29, 2163-2174	10.3	88
534	Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer. <i>British Journal of Cancer</i> , <b>2018</b> , 119, 1208-1214	8.7	111
533	Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , <b>2018</b> , 19, 1437-1448	21.7	210
532	Preparing for the incoming wave of biosimilars in oncology. <i>ESMO Open</i> , <b>2018</b> , 3, e000420	6	5
531	Cancer Core Europe: A European cancer research alliance realizing a research infrastructure with critical mass and programmatic approach to cure cancer in the 21st century. <i>European Journal of Cancer</i> , <b>2018</b> , 103, 155-159	7.5	11
530	Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study. <i>Lancet Oncology</i> , <b>2018</b> , 19, 1372-1384	21.7	193
529	Strategies to design clinical studies to identify predictive biomarkers in cancer research. <i>Cancer Treatment Reviews</i> , <b>2017</b> , 53, 79-97	14.4	64
528	The expanding role of immunotherapy. <i>Cancer Treatment Reviews</i> , <b>2017</b> , 54, 74-86	14.4	72
527	Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials. <i>Annals of Oncology</i> , <b>2017</b> , 28, 1713-1729	10.3	454
526	Professional burnout in European young oncologists: results of the European Society for Medical Oncology (ESMO) Young Oncologists Committee Burnout Survey. <i>Annals of Oncology</i> , <b>2017</b> , 28, 1590-1596	10.3	67
525	Primary tumor sidedness has an impact on prognosis and treatment outcome in metastatic colorectal cancer: results from two randomized first-line panitumumab studies. <i>Annals of Oncology</i> , <b>2017</b> , 28, 1862-1868	10.3	126
524	Targeting the fibroblast growth factor receptor 2 in gastric cancer: promise or pitfall?. <i>Annals of Oncology</i> , <b>2017</b> , 28, 1207-1216	10.3	22
523	Optimization of Mutational Analysis Confirms Improvement in Patient Selection for Clinical Benefit to Anti-EGFR Treatment in Metastatic Colorectal Cancer. <i>Molecular Cancer Therapeutics</i> , <b>2017</b> , 16, 1999-2007	6.1	8

522	A Phase Ib Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Cobimetinib and Duligotuzumab in Patients with Previously Treated Locally Advanced or Metastatic Cancers with Mutant KRAS. <i>Oncologist</i> , <b>2017</b> , 22, 1024-e89	5.7	15
521	A First-in-Human, Phase I, Dose-Escalation Study of TAK-117, a Selective PI3K $\alpha$ Isoform Inhibitor, in Patients with Advanced Solid Malignancies. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 5015-5023	12.9	51
520	Baseline carcinoembryonic antigen as a predictive factor of ramucirumab efficacy in RAISE, a second-line metastatic colorectal carcinoma phase III trial. <i>European Journal of Cancer</i> , <b>2017</b> , 78, 61-69	7.5	21
519	Analysis of mutant allele fractions in driver genes in colorectal cancer - biological and clinical insights. <i>Molecular Oncology</i> , <b>2017</b> , 11, 1263-1272	7.9	20
518	A Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab with or without Alpelisib in Metastatic -Mutant Colorectal Cancer. <i>Cancer Discovery</i> , <b>2017</b> , 7, 610-619	24.4	132
517	Concordance of blood- and tumor-based detection of RAS mutations to guide anti-EGFR therapy in metastatic colorectal cancer. <i>Annals of Oncology</i> , <b>2017</b> , 28, 1294-1301	10.3	107
516	Targeting c-MET in gastrointestinal tumours: rationale, opportunities and challenges. <i>Nature Reviews Clinical Oncology</i> , <b>2017</b> , 14, 562-576	19.4	102
515	Adjuvant FOLFOX +/- cetuximab in full RAS and BRAF wildtype stage III colon cancer patients. <i>Annals of Oncology</i> , <b>2017</b> , 28, 824-830	10.3	31
514	Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer. <i>Nature Reviews Cancer</i> , <b>2017</b> , 17, 79-92	31.3	423
513	Prognostic Value of BRAF and KRAS Mutations in MSI and MSS Stage III Colon Cancer. <i>Journal of the National Cancer Institute</i> , <b>2017</b> , 109,	9.7	138
512	Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumab. <i>Annals of Oncology</i> , <b>2017</b> , 28, 2932-2942	10.3	63
511	The Cancer Moonshot from a European perspective. <i>Lancet Oncology, The</i> , <b>2017</b> , 18, e626	21.7	
510	A Multi-Arm Phase I Study of the PI3K/mTOR Inhibitors PF-04691502 and Gedatolisib (PF-05212384) plus Irinotecan or the MEK Inhibitor PD-0325901 in Advanced Cancer. <i>Targeted Oncology</i> , <b>2017</b> , 12, 775-785	5	46
509	ESMO-Magnitude of Clinical Benefit Scale version 1.1. <i>Annals of Oncology</i> , <b>2017</b> , 28, 2340-2366	10.3	266
508	A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer. <i>BMC Cancer</i> , <b>2017</b> , 17, 646	4.8	12
507	-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: a subgroup analysis of the Western European cohort of the MPACT trial. <i>OncoTargets and Therapy</i> , <b>2017</b> , 10, 591-596	4.4	17
506	HELOISE: Phase IIb Randomized Multicenter Study Comparing Standard-of-Care and Higher-Dose Trastuzumab Regimens Combined With Chemotherapy as First-Line Therapy in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 2558-2567	2.2	73
505	Pharmacokinetic/Pharmacodynamic Modeling for Drug Development in Oncology. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , <b>2017</b> , 37, 210-215	7.1	15

504	Comparison between MRI and pathology in the assessment of tumour regression grade in rectal cancer. <i>British Journal of Cancer</i> , <b>2017</b> , 117, 1478-1485	8.7	64
503	Cancer: A precision approach to tumour treatment. <i>Nature</i> , <b>2017</b> , 548, 40-41	50.4	20
502	Exposure-Response Analyses of Ramucirumab from Two Randomized, Phase III Trials of Second-line Treatment for Advanced Gastric or Gastroesophageal Junction Cancer. <i>Molecular Cancer Therapeutics</i> , <b>2017</b> , 16, 2215-2222	6.1	27
501	BRAF mutant colorectal cancer: prognosis, treatment, and new perspectives. <i>Annals of Oncology</i> , <b>2017</b> , 28, 2648-2657	10.3	133
500	Exposure-response relationship of ramucirumab in patients with advanced second-line colorectal cancer: exploratory analysis of the RAISE trial. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2017</b> , 80, 599-608	3.5	12
499	Reply to the letter to the editor 'Addressing the quality of the ESMO-MCBS' by Del Paggio. <i>Annals of Oncology</i> , <b>2017</b> , 28, 2031-2032	10.3	
498	Cell-Free DNA in Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis. <i>Oncologist</i> , <b>2017</b> , 22, 1049-1055	5.7	56
497	Proxies of quality of life in metastatic colorectal cancer: analyses in the RECURSE trial. <i>ESMO Open</i> , <b>2017</b> , 2, e000261	6	16
496	QTwIST analysis of the RECURSE trial of trifluridine/tipiracil in metastatic colorectal cancer. <i>ESMO Open</i> , <b>2017</b> , 2, e000284	6	12
495	Analysis of persistence and antibiotic response in colorectal cancer. <i>Science</i> , <b>2017</b> , 358, 1443-1448	33.3	578
494	Reply to the letter to the editor 'Can we trust burnout research?' by Bianchi et al. <i>Annals of Oncology</i> , <b>2017</b> , 28, 2625-2626	10.3	1
493	Overexpression of Yes Associated Protein 1, an Independent Prognostic Marker in Patients With Pancreatic Ductal Adenocarcinoma, Correlated With Liver Metastasis and Poor Prognosis. <i>Pancreas</i> , <b>2017</b> , 46, 913-920	2.6	38
492	Improving the Armamentarium of PI3K Inhibitors with Isoform-Selective Agents: A New Light in the Darkness. <i>Cancer Discovery</i> , <b>2017</b> , 7, 666-669	24.4	21
491	Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOX. <i>European Journal of Cancer</i> , <b>2017</b> , 82, 16-24	7.5	28
490	mTORC1-dependent AMD1 regulation sustains polyamine metabolism in prostate cancer. <i>Nature</i> , <b>2017</b> , 547, 109-113	50.4	92
489	Dalotuzumab in chemorefractory KRAS exon 2 mutant colorectal cancer: Results from a randomised phase II/III trial. <i>International Journal of Cancer</i> , <b>2017</b> , 140, 431-439	7.5	3
488	Prognostic and Predictive Relevance of Primary Tumor Location in Patients With RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses of the CRYSTAL and FIRE-3 Trials. <i>JAMA Oncology</i> , <b>2017</b> , 3, 194-201	13.4	409
487	Efficacy of trifluridine and tipiracil (TAS-102) versus placebo, with supportive care, in a randomized, controlled trial of patients with metastatic colorectal cancer from Spain: results of a subgroup analysis of the phase 3 RECURSE trial. <i>Clinical and Translational Oncology</i> , <b>2017</b> , 19, 227-235	3.6	18



486	A First-in-Human Phase I Study of the ATP-Competitive AKT Inhibitor Ipatasertib Demonstrates Robust and Safe Targeting of AKT in Patients with Solid Tumors. <i>Cancer Discovery</i> , <b>2017</b> , 7, 102-113	24.4	105
485	Detailed statistical assessment of the characteristics of the ESMO Magnitude of Clinical Benefit Scale (ESMO-MCBS) threshold rules. <i>ESMO Open</i> , <b>2017</b> , 2, e000216	6	14
484	Incorporating BEAMing technology as a liquid biopsy into clinical practice for the management of colorectal cancer patients: an expert taskforce review. <i>Annals of Oncology</i> , <b>2017</b> , 28, 2943-2949	10.3	51
483	Debio 1347, an oral FGFR inhibitor: Results from a first-in-human, phase I dose-escalation study in patients with FGFR genomically activated advanced solid tumors.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 2500-2500	2.2	10
482	First-in-human phase 1/2 study of MCLA-128, a full length IgG1 bispecific antibody targeting HER2 and HER3: Final phase 1 data and preliminary activity in HER2+ metastatic breast cancer (MBC).. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 2522-2522	2.2	22
481	CanStem111P trial: A phase III study of napabucasin (BBI-608) plus nab-paclitaxel (nab-PTX) with gemcitabine (gem) in adult patients with metastatic pancreatic adenocarcinoma (mPDAC).. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, TPS4148-TPS4148	2.2	8
480	Placental growth factor and the angiogenic environment based on analysis of baseline plasma biomarkers from the VELOUR trial.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 592-592	2.2	7
479	Baseline absolute neutrophil counts (ANC) and survival in second-line metastatic colorectal cancer (mCRC) patients (pts).. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 713-713	2.2	1
478	Pharmacokinetic/Pharmacodynamic Modeling for Drug Development in Oncology. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , <b>2017</b> , 37, 210-215	7.1	17
477	Pancreatic cancer heterogeneity and response to Mek inhibition. <i>Oncogene</i> , <b>2017</b> , 36, 5639-5647	9.2	14
476	Impact of early trials in molecularly-characterized patients (pts) with head and neck cancer (HNC).. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 6031-6031	2.2	1
475	Molecular markers to predict response to selective fibroblast growth factor receptor inhibitors (FGFRinh) in patients (pts) with FGFR-amplified (amp) or mutated (mut) tumors.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 2581-2581	2.2	
474	Rationale and Design for the LUME-Colon 1 Study: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Nintedanib Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in Patients With Advanced Colorectal Cancer Refractory to Standard Treatment. <i>Clinical Colorectal Cancer</i> , <b>2016</b> , 15, 91-94.e1	3.8	16
473	First-in-Man Dose-Escalation Study of the Selective BRAF Inhibitor RG7256 in Patients with BRAF V600-Mutated Advanced Solid Tumors. <i>Targeted Oncology</i> , <b>2016</b> , 11, 149-56	5	1
472	Tankyrase Inhibition Blocks Wnt/ECatenin Pathway and Reverts Resistance to PI3K and AKT Inhibitors in the Treatment of Colorectal Cancer. <i>Clinical Cancer Research</i> , <b>2016</b> , 22, 644-56	12.9	114
471	Epigenetic profiling to classify cancer of unknown primary: a multicentre, retrospective analysis. <i>Lancet Oncology</i> , <b>2016</b> , 17, 1386-1395	21.7	251
470	Improving survival and local control in rectal cancer in Catalonia (Spain) in the context of centralisation: A full cycle audit assessment. <i>European Journal of Surgical Oncology</i> , <b>2016</b> , 42, 1873-1880	3.6	16
469	Sequence variation in mature microRNA-608 and benefit from neo-adjuvant treatment in locally advanced rectal cancer patients. <i>Carcinogenesis</i> , <b>2016</b> , 37, 852-7	4.6	13



468	Emerging tyrosine kinase inhibitors for the treatment of metastatic colorectal cancer. <i>Expert Opinion on Emerging Drugs</i> , <b>2016</b> , 21, 267-82	3.7	6
467	Subgroup analysis in RAISE: a randomized, double-blind phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patients with metastatic colorectal carcinoma progression. <i>Annals of Oncology</i> , <b>2016</b> , 27, 2082-2090	10.3	40
466	Epigenetic Homogeneity Within Colorectal Tumors Predicts Shorter Relapse-Free and Overall Survival Times for Patients With Locoregional Cancer. <i>Gastroenterology</i> , <b>2016</b> , 151, 961-972	13.3	30
465	Quality of life during first-line FOLFOX4+panitumumab in wild-type metastatic colorectal carcinoma: results from a randomised controlled trial. <i>ESMO Open</i> , <b>2016</b> , 1, e000041	6	13
464	Applying the ESMO-Magnitude of Clinical Benefit Scale in real life. <i>ESMO Open</i> , <b>2016</b> , 1, e000090	6	3
463	The European Cancer Patient's Bill of Rights, update and implementation 2016. <i>ESMO Open</i> , <b>2016</b> , 1, e000127	6	25
462	Integrated genomic analysis of colorectal cancer progression reveals activation of EGFR through demethylation of the EREG promoter. <i>Oncogene</i> , <b>2016</b> , 35, 6403-6415	9.2	43
461	Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer. <i>Cancer Research</i> , <b>2016</b> , 76, 4504-15	10.1	63
460	Gastrointestinal cancer: Light and shade of intrahepatic arterial radiotherapy in mCRC. <i>Nature Reviews Clinical Oncology</i> , <b>2016</b> , 13, 467-8	19.4	1
459	Phase II study of necitumumab plus modified FOLFOX6 as first-line treatment in patients with locally advanced or metastatic colorectal cancer. <i>British Journal of Cancer</i> , <b>2016</b> , 114, 372-80	8.7	22
458	CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer. <i>Annals of Oncology</i> , <b>2016</b> , 27, 654-60	10.3	62
457	Prognostic Effect of BRAF and KRAS Mutations in Patients With Stage III Colon Cancer Treated With Leucovorin, Fluorouracil, and Oxaliplatin With or Without Cetuximab: A Post Hoc Analysis of the PETACC-8 Trial. <i>JAMA Oncology</i> , <b>2016</b> , 2, 643-653	13.4	87
456	Current and advancing treatments for metastatic colorectal cancer. <i>Expert Opinion on Biological Therapy</i> , <b>2016</b> , 16, 93-110	5.4	26
455	Awareness, Understanding, and Adoption of Precision Medicine to Deliver Personalized Treatment for Patients With Cancer: A Multinational Survey Comparison of Physicians and Patients. <i>Oncologist</i> , <b>2016</b> , 21, 292-300	5.7	28
454	Immunotherapy for Gastric Cancer: A Focus on Immune Checkpoints. <i>Targeted Oncology</i> , <b>2016</b> , 11, 469-73		31
453	Positron emission tomography response evaluation from a randomized phase III trial of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas. <i>Annals of Oncology</i> , <b>2016</b> , 27, 648-53	10.3	29
452	The First-in-class Anti-EGFR Antibody Mixture Sym004 Overcomes Cetuximab Resistance Mediated by EGFR Extracellular Domain Mutations in Colorectal Cancer. <i>Clinical Cancer Research</i> , <b>2016</b> , 22, 3260-7	12.9	48
451	Aflibercept Plus FOLFIRI vs. Placebo Plus FOLFIRI in Second-Line Metastatic Colorectal Cancer: a Post Hoc Analysis of Survival from the Phase III VELOUR Study Subsequent to Exclusion of Patients who had Recurrence During or Within 6 Months of Completing Adjuvant Oxaliplatin-Based Therapy. <i>Targeted Oncology</i> , <b>2016</b> , 11, 383-400	5	33

450 mTOR Inhibition Beyond Rapalogs **2016**, 251-275

0

449 Abstract CT050: A Phase I/II Study of MCLA-128, a full length IgG1 Bispecific Antibody Targeting HER2 and HER3, in Patients with Solid Tumors **2016**,

12

448 Abstract CT068: A randomized phase II, double-blind study to evaluate the efficacy and safety of galunisertib+gemcitabine (GG) or gemcitabine+placebo (GP) in patients with unresectable pancreatic cancer (PC) **2016**,

9

447 Vemurafenib in Patients with Erdheim-Chester Disease (ECD) and Langerhans Cell Histiocytosis (LCH) Harboring BRAFV600 Mutations: A Cohort of the Histology-Independent VE-Basket Study. *Blood*, **2016**, 128, 480-480

2.2 3

446 POSEIDON trial phase 1b results: Safety and preliminary efficacy of the isoform selective PI3K inhibitor taselisib (GDC-0032) combined with tamoxifen in hormone receptor (HR) positive, HER2-negative metastatic breast cancer (MBC) patients (pts) - including response monitoring by plasma circulating tumor (ct) DNA.. *Journal of Clinical Oncology*, **2016**, 34, 2520-2520

2.2 6

445 Matching degree between PI3K/AKT/mTOR (PAM) pathway mutations (mut) and therapy (ttx) as predictor of clinical benefit (ClinBen) in early trials.. *Journal of Clinical Oncology*, **2016**, 34, 2572-2572

2.2 2

444 Phase 2 results: Encorafenib (ENCO) and cetuximab (CETUX) with or without alpelisib (ALP) in patients with advanced BRAF-mutant colorectal cancer (BRAFM CRC).. *Journal of Clinical Oncology*, **2016**, 34, 3544-3544

2.2 51

443 MAESTRO: A randomized, double-blind phase III study of evofosfamide (Evo) in combination with gemcitabine (Gem) in previously untreated patients (pts) with metastatic or locally advanced unresectable pancreatic ductal adenocarcinoma (PDAC).. *Journal of Clinical Oncology*, **2016**, 34, 4007-4007

2.2 28

442 A phase II, double-blind study of galunisertib+gemcitabine (GG) vs gemcitabine+placebo (GP) in patients (pts) with unresectable pancreatic cancer (PC).. *Journal of Clinical Oncology*, **2016**, 34, 4019-4019

2.2 26

441 Preliminary safety data from KEYNOTE-059: Pembrolizumab plus 5-fluorouracil (5-FU) and cisplatin for first-line treatment of advanced gastric cancer.. *Journal of Clinical Oncology*, **2016**, 34, 4037-4037

2.2 10

440 Comprehensive profiling of biliary tract cancers (BTC) to reveal molecular heterogeneity with implications for matched targeted therapies (MTT).. *Journal of Clinical Oncology*, **2016**, 34, 4085-4085

2.2 2

439 Impact of molecular prescreening for genomically-guided trials in head and neck cancer (HNC).. *Journal of Clinical Oncology*, **2016**, 34, 6030-6030

2.2 0

438 A randomized, double-blind, placebo-controlled study of ibrutinib, a Bruton tyrosine kinase inhibitor, with nab-paclitaxel and gemcitabine in the first-line treatment of patients with metastatic pancreatic adenocarcinoma (RESOLVE).. *Journal of Clinical Oncology*, **2016**, 34, TPS2601-TPS2601

2.2 4

437 A phase 1, multicenter, dose-escalation study of PRN1371, an irreversible covalent FGFR1-4 kinase inhibitor, in patients with advanced solid tumors, followed by expansion cohorts in patients with FGFR genetic alterations.. *Journal of Clinical Oncology*, **2016**, 34, TPS2602-TPS2602

2.2 2

436 Pembrolizumab versus paclitaxel as second-line therapy for advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Phase 3 KEYNOTE-061 study.. *Journal of Clinical Oncology*, **2016**, 34, TPS4137-TPS4137

2.2 4

435 KEYNOTE-062: Phase 3 study of pembrolizumab alone or in combination with chemotherapy versus chemotherapy alone as first-line therapy for advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma.. *Journal of Clinical Oncology*, **2016**, 34, TPS4138-TPS4138

2.2 1

434 TAGS, a randomized, double-blind, phase 3 study evaluating TAS-102 plus best supportive care vs placebo plus best supportive care in patients with metastatic gastric cancer refractory to standard treatments.. *Journal of Clinical Oncology*, **2016**, 34, TPS4141-TPS4141

2.2 1

433 Pembrolizumab (MK-3475) plus 5-fluorouracil (5-FU) and cisplatin for first-line treatment of advanced gastric cancer: Preliminary safety data from KEYNOTE-059.. *Journal of Clinical Oncology*, **2016**, 34, 161-161

2.2 5

432	Evofosfamide (TH-302) in combination with gemcitabine in previously untreated patients with metastatic or locally advanced unresectable pancreatic ductal adenocarcinoma: Primary analysis of the randomized, double-blind phase III MAESTRO study.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 193-193	2.2	17
431	A phase Ib dose escalation, safety, and tolerability study of sonidegib in combination with gemcitabine in patients with locally advanced or metastatic pancreatic adenocarcinoma.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 371-371	2.2	7
430	Validation of the prognostic impact of lymphocyte infiltration (LI) in patients (pts) with stage III colon cancer (CC) treated with adjuvant FOLFOX+/- cetuximab: A PETACC8 translational study.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 553-553	2.2	3
429	Prognostic impact of primary tumor site location in metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 578-578	2.2	1
428	TAS-102 versus placebo plus best supportive care in patients with metastatic colorectal cancer refractory to standard therapies: Final survival results of the phase III RECURSE trial.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 634-634	2.2	8
427	TAS-102 versus placebo (PBO) in patients (pts) ≥5 years (y) with metastatic colorectal cancer (mCRC): An age-based analysis of the recourse trial.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 638-638	2.2	2
426	Phase III RECURSE trial of TAS-102 versus placebo with best supportive care in patients with metastatic colorectal cancer: Geographic subgroups.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 646-646	2.2	6
425	Survival determinants with matched targeted therapies in BRAF mutant metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 649-649	2.2	1
424	Pembrolizumab (MK-3475) versus paclitaxel as second-line therapy for advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Phase 3 KEYNOTE-061 study.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, TPS183-TPS183	2.2	10
423	KEYNOTE-062: Phase III study of pembrolizumab (MK-3475) alone or in combination with chemotherapy versus chemotherapy alone as first-line therapy for advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, TPS185-TPS185	2.2	20
422	A randomized, multicenter, double-blind, placebo-controlled study of the Bruton tyrosine kinase inhibitor, ibrutinib, versus placebo in combination with nab-paclitaxel and gemcitabine in the first-line treatment of patients with metastatic pancreatic adenocarcinoma (RESOLVE).. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, TPS483-TPS483	2.2	5
421	Molecular prescreening (MP) to treat patients (pts) with advanced pancreatic cancer (PC) in early clinical trials.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 272-272	2.2	
420	Analysis of RSPO gene expression in solid tumors.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, e23235-e23235	2.2	0
419	Clonality patterns of driver mutations (mut) to reveal spatial-temporal genomic heterogeneity in colorectal cancer (CRC).. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 3509-3509	2.2	
418	Comparison of three molecular methods to detect mutations in KRAS, NRAS, BRAF and PIK3CA in metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 3559-3559	2.2	
417	ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. <i>Annals of Oncology</i> , <b>2016</b> , 27, 1386-422	10.3	1683
416	Radiological imaging markers predicting clinical outcome in patients with metastatic colorectal carcinoma treated with regorafenib: post hoc analysis of the CORRECT phase III trial (RadioCORRECT study). <i>ESMO Open</i> , <b>2016</b> , 1, e000111	6	22
415	Career opportunities and benefits for young oncologists in the European Society for Medical Oncology (ESMO). <i>ESMO Open</i> , <b>2016</b> , 1, e000107	6	8

414	ESMO - Magnitude of Clinical Benefit Scale V.1.0 questions and answers. <i>ESMO Open</i> , <b>2016</b> , 1, e000100	6	11
413	ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016. <i>ESMO Open</i> , <b>2016</b> , 1, e000097	6	59
412	Spectrum of Gene Mutations in Colorectal Cancer: Implications for Treatment. <i>Cancer Journal (Sudbury, Mass)</i> , <b>2016</b> , 22, 149-55	2.2	14
411	Biosimilars: a position paper of the European Society for Medical Oncology, with particular reference to oncology prescribers. <i>ESMO Open</i> , <b>2016</b> , 1, e000142	6	79
410	PAN-EX: a pooled analysis of two trials of neoadjuvant chemotherapy followed by chemoradiotherapy in MRI-defined, locally advanced rectal cancer. <i>Annals of Oncology</i> , <b>2016</b> , 27, 1557-65	10.3	47
409	Nanofluidic Digital PCR and Extended Genotyping of RAS and BRAF for Improved Selection of Metastatic Colorectal Cancer Patients for Anti-EGFR Therapies. <i>Molecular Cancer Therapeutics</i> , <b>2016</b> , 15, 1106-12	6.1	12
408	Ramucirumab in metastatic colorectal cancer: evidence to date and place in therapy. <i>Therapeutic Advances in Medical Oncology</i> , <b>2016</b> , 8, 230-42	5.4	45
407	Brexit: a European perspective. <i>Lancet Oncology, The</i> , <b>2016</b> , 17, 558-9	21.7	11
406	Diagnosis and treatment of hepatocellular carcinoma. Update consensus document from the AEEH, SEOM, SERAM, SERVEI and SETH. <i>Medicina Clínica (English Edition)</i> , <b>2016</b> , 146, 511.e1-511.e22	0.3	1
405	Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer. <i>British Journal of Cancer</i> , <b>2016</b> , 115, 188-94	8.7	52
404	Letter to the editor regarding the paper by A. Lozano-Blaquez et al. Differences in cancer drug assessment between Spain and the United Kingdom. <i>European Journal of Cancer</i> , <b>2016</b> , 67, 55-56	7.5	1
403	Biomarker analyses in REGARD gastric/GEJ carcinoma patients treated with VEGFR2-targeted antibody ramucirumab. <i>British Journal of Cancer</i> , <b>2016</b> , 115, 974-982	8.7	44
402	Methodological aspects of the molecular and histological study of prostate cancer: focus on PTEN. <i>Methods</i> , <b>2015</b> , 77-78, 25-30	4.6	16
401	SPARC Expression Did Not Predict Efficacy of nab-Paclitaxel plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis of the Phase III MPACT Trial. <i>Clinical Cancer Research</i> , <b>2015</b> , 21, 4811-8	12.9	101
400	Short- and Long-Term Quality of Life and Bowel Function in Patients With MRI-Defined, High-Risk, Locally Advanced Rectal Cancer Treated With an Intensified Neoadjuvant Strategy in the Randomized Phase 2 EXPERT-C Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2015</b> , 93, 303-12	4	13
399	Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial. <i>Lancet Oncology, The</i> , <b>2015</b> , 16, 937-48	21.7	240
398	Prognostic role of the LCS6 KRAS variant in locally advanced rectal cancer: results of the EXPERT-C trial. <i>Annals of Oncology</i> , <b>2015</b> , 26, 1936-1941	10.3	18
397	Systemic Therapy for Patients with Colorectal Cancer: State of the Art <b>2015</b> , 109-132		

396	Impact of early tumour shrinkage and resection on outcomes in patients with wild-type RAS metastatic colorectal cancer. <i>European Journal of Cancer</i> , <b>2015</b> , 51, 1231-42	7.5	53
395	Personalizing colon cancer adjuvant therapy: selecting optimal treatments for individual patients. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 1787-96	2.2	213
394	Optimal design of trials to demonstrate the utility of genomically-guided therapy: Putting Precision Cancer Medicine to the test. <i>Molecular Oncology</i> , <b>2015</b> , 9, 940-50	7.9	24
393	Regorafenib plus modified FOLFOX6 as first-line treatment of metastatic colorectal cancer: A phase II trial. <i>European Journal of Cancer</i> , <b>2015</b> , 51, 942-9	7.5	32
392	Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. <i>Lancet Oncology</i> , <b>2015</b> , 16, 499-508	21.7	568
391	A phase I trial of intravenous catumaxomab: a bispecific monoclonal antibody targeting EpCAM and the T cell coreceptor CD3. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2015</b> , 75, 1065-73	3.5	38
390	Randomized trial of TAS-102 for refractory metastatic colorectal cancer. <i>New England Journal of Medicine</i> , <b>2015</b> , 372, 1909-19	59.2	720
389	Fibroblast Growth Factor (FGF) Receptor/FGF Inhibitors: Novel Targets and Strategies for Optimization of Response of Solid Tumors. <i>Seminars in Oncology</i> , <b>2015</b> , 42, 801-19	5.5	64
388	MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer. <i>Clinical Cancer Research</i> , <b>2015</b> , 21, 5499-5510	12.9	13
387	Elucidating the molecular aspects of colorectal cancer and their clinical importance. <i>Colorectal Cancer</i> , <b>2015</b> , 4, 175-183	0.8	
386	First-Line Treatment of Metastatic Colorectal Cancer: Interpreting FIRE-3, PEAK, and CALGB/SWOG 80405. <i>Current Treatment Options in Oncology</i> , <b>2015</b> , 16, 52	5.4	61
385	Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets. <i>Cancer Discovery</i> , <b>2015</b> , 5, 1164-1177	24.4	581
384	Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 4176-87	2.2	347
383	A Randomized Phase II/III Study of Dalotuzumab in Combination With Cetuximab and Irinotecan in Chemorefractory, KRAS Wild-Type, Metastatic Colorectal Cancer. <i>Journal of the National Cancer Institute</i> , <b>2015</b> , 107, djv258	9.7	55
382	The consensus molecular subtypes of colorectal cancer. <i>Nature Medicine</i> , <b>2015</b> , 21, 1350-6	50.5	2332
381	Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations. <i>New England Journal of Medicine</i> , <b>2015</b> , 373, 726-36	59.2	1172
380	Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 3401-8	2.2	273
379	Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer: Final Results of the NO16968 Randomized Controlled Phase III Trial. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 3733-40	2.2	159



378	First-in-Human Study of PF-05212384 (PKI-587), a Small-Molecule, Intravenous, Dual Inhibitor of PI3K and mTOR in Patients with Advanced Cancer. <i>Clinical Cancer Research</i> , <b>2015</b> , 21, 1888-95	12.9	76
377	Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: a randomized phase II study. <i>Annals of Oncology</i> , <b>2015</b> , 26, 149-156	10.3	81
376	Pragmatic issues in biomarker evaluation for targeted therapies in cancer. <i>Nature Reviews Clinical Oncology</i> , <b>2015</b> , 12, 197-212	19.4	139
375	Anticancer activity of the type I insulin-like growth factor receptor antagonist, ganitumab, in combination with the death receptor 5 agonist, conatumumab. <i>Targeted Oncology</i> , <b>2015</b> , 10, 65-76	5	21
374	Abituzumab combined with cetuximab plus irinotecan versus cetuximab plus irinotecan alone for patients with KRAS wild-type metastatic colorectal cancer: the randomised phase I/II POSEIDON trial. <i>Annals of Oncology</i> , <b>2015</b> , 26, 132-140	10.3	66
373	Carlumab, an anti-C-C chemokine ligand 2 monoclonal antibody, in combination with four chemotherapy regimens for the treatment of patients with solid tumors: an open-label, multicenter phase 1b study. <i>Targeted Oncology</i> , <b>2015</b> , 10, 111-23	5	107
372	Overcoming Resistance to Anti-EGFR Therapy in Colorectal Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , <b>2015</b> , e149-56	7.1	43
371	Cyclin E amplification/overexpression is associated with poor prognosis in gastric cancer. <i>Annals of Oncology</i> , <b>2015</b> , 26, 438-9	10.3	15
370	Phase I study of FOLFIRI plus pimasertib as second-line treatment for KRAS-mutated metastatic colorectal cancer. <i>British Journal of Cancer</i> , <b>2015</b> , 112, 1874-81	8.7	25
369	Safety and Activity of the First-in-Class Sym004 Anti-EGFR Antibody Mixture in Patients with Refractory Colorectal Cancer. <i>Cancer Discovery</i> , <b>2015</b> , 5, 598-609	24.4	65
368	Genomic classifier ColoPrint predicts recurrence in stage II colorectal cancer patients more accurately than clinical factors. <i>Oncologist</i> , <b>2015</b> , 20, 127-33	5.7	79
367	Safety and Pharmacokinetics/Pharmacodynamics of the First-in-Class Dual Action HER3/EGFR Antibody MEHD7945A in Locally Advanced or Metastatic Epithelial Tumors. <i>Clinical Cancer Research</i> , <b>2015</b> , 21, 2462-70	12.9	42
366	Pharmacokinetic and pharmacodynamic evaluation of aflibercept for the treatment of colorectal cancer. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2015</b> , 11, 995-1004	5.5	2
365	Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma. <i>Nature Communications</i> , <b>2015</b> , 6, 8839	17.4	416
364	Optimising translational oncology in clinical practice: strategies to accelerate progress in drug development. <i>Cancer Treatment Reviews</i> , <b>2015</b> , 41, 129-35	14.4	14
363	nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial. <i>Journal of the National Cancer Institute</i> , <b>2015</b> , 107,	9.7	368
362	A phase Ib dose-escalation study of the oral pan-PI3K inhibitor buparlisib (BKM120) in combination with the oral MEK1/2 inhibitor trametinib (GSK1120212) in patients with selected advanced solid tumors. <i>Clinical Cancer Research</i> , <b>2015</b> , 21, 730-8	12.9	215
361	Detection, Characterization, and Inhibition of FGFR-TACC Fusions in IDH Wild-type Glioma. <i>Clinical Cancer Research</i> , <b>2015</b> , 21, 3307-17	12.9	176



360	Intrinsic cancer subtypes--next steps into personalized medicine. <i>Cellular Oncology (Dordrecht)</i> , <b>2015</b> , 38, 3-16	7.2	20
359	Efficacy, safety, pharmacokinetics and pharmacodynamics of SAR245409 (voxtalisib, XL765), an orally administered phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor: a phase 1 expansion cohort in patients with relapsed or refractory lymphoma. <i>Leukemia and Lymphoma</i> , <b>2015</b> , 56, 1768-1770	1.9	25
358	Prognostic factors of survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer. <i>Oncologist</i> , <b>2015</b> , 20, 143-50	5.7	99
357	Abstract CT110: Randomized phase II study of duligotuzumab + FOLFIRI versus cetuximab + FOLFIRI in 2nd-line patients with KRAS wild-type (wt) metastatic colorectal cancer (mCRC) <b>2015</b> ,		9
356	Updated efficacy of the MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E mutated (BRAFM) metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 103-103	2.2	34
355	First-in-human, phase I, dose-escalation study of selective PI3K $\alpha$ isoform inhibitor MLN1117 in patients (pts) with advanced solid malignancies.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 2501-2501	2.2	5
354	CEA-targeted engineered IL2: Clinical confirmation of tumor targeting and evidence of intra-tumoral immune activation.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 3016-3016	2.2	9
353	Analysis of DNA mismatch repair (MMR) and clinical outcome in stage III colon cancers from patients (pts) treated with adjuvant FOLFOX +/- cetuximab in the PETACC8 and NCCTG N0147 adjuvant trials.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 3506-3506	2.2	2
352	Prognostic value of BRAF V600E and KRAS exon 2 mutations in microsatellite stable (MSS), stage III colon cancers (CC) from patients (pts) treated with adjuvant FOLFOX +/- cetuximab: A pooled analysis of 3934 pts from the PETACC8 and N0147 trials.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 3507-3507	2.2	6
351	Toxicity and quality of life data from SCOT: An international phase III randomized (1:1) noninferiority trial comparing 3 vs 6 months of oxaliplatin-based adjuvant chemotherapy.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 3514-3514	2.2	5
350	Molecular subtypes and outcomes in regorafenib-treated patients with metastatic colorectal cancer (mCRC) enrolled in the CORRECT trial.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 3558-3558	2.2	15
349	Outcome evolution of matched molecular targeted agents (MTAs) in metastatic colorectal cancer (CRC) patients (pts): VHIO experience.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 3602-3602	2.2	1
348	METGastric: A phase III study of onartuzumab plus mFOLFOX6 in patients with metastatic HER2-negative (HER2-) and MET-positive (MET+) adenocarcinoma of the stomach or gastroesophageal junction (GEC).. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 4012-4012	2.2	65
347	Candidate biomarker analyses in gastric or gastro-esophageal junction carcinoma: REGARD trial of single-agent ramucirumab (RAM) vs. placebo (PL).. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 4029-4029	2.2	3
346	LUME-Colon 1: A double-blind, randomized phase III study of nintedanib plus best supportive care (BSC) versus placebo plus BSC in patients with colorectal cancer (CRC) refractory to standard therapies.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, TPS3625-TPS3625	2.2	1
345	MErCuRIC1: A Phase I study of MEK1/2 inhibitor PD-0325901 with cMET inhibitor crizotinib in RASMT and RASWT (with aberrant c-MET) metastatic colorectal cancer (mCRC) patients.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, TPS3632-TPS3632	2.2	3
344	Phase III study of regorafenib versus placebo as maintenance therapy in RAS wild type metastatic colorectal cancer (RAVELLO trial).. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, TPS3634-TPS3634	2.2	2
343	A randomized, double-blind, placebo-controlled phase III study of cisplatin plus a fluoropyrimidine with or without ramucirumab as first-line therapy in patients with metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma (RAINFALL, NCT02314117).. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, TPS4131-TPS4131	2.2	4

342	Multicohort phase II KEYNOTE-059 study of pembrolizumab (MK-3475) for recurrent or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, TPS4135-TPS4135		
341	Exposure-response (E-R) relationship of ramucirumab (RAM) from two global, randomized, double-blind, phase 3 studies of patients (Pts) with advanced second-line gastric cancer.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 121-121	2.2	15
340	RAISE: A randomized, double-blind, multicenter phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab (RAM) or placebo (PBO) in patients (pts) with metastatic colorectal carcinoma (CRC) progressive during or following first-line combination therapy with bevacizumab (bev), oxaliplatin (ox), and a fluoropyrimidine (fp).. <i>Journal of Clinical Oncology</i> , <b>2015</b> ,	2.2	8
339	Improving access to molecularly defined clinical trials for patients with colorectal cancer: The EORTC SPECTAColor platform.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 575-575	2.2	4
338	GAIN-(C): Efficacy and safety analysis of imgatuzumab (GA201), a novel dual-acting monoclonal antibody (mAb) designed to enhance antibody-dependent cellular cytotoxicity (ADCC), in combination with FOLFIRI compared to cetuximab plus FOLFIRI in second-line KRAS exon 2 wild type (e2WT) or with FOLFIRI alone in mutated (e2MT) metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 663-663	2.2	10
337	Quality of life (QoL) during first-line treatment with FOLFOX4 with or without panitumumab (pmab) in RAS wild-type (WT) metastatic colorectal carcinoma (mCRC).. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 693-693	2.2	2
336	Subgroup analysis of patients with metastatic colorectal cancer (mCRC) treated with regorafenib (REG) in the CORRECT trial who had progression-free survival (PFS) longer than 4 months.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 710-710	2.2	2
335	Phase III study of regorafenib versus placebo as maintenance therapy in RAS wild type metastatic colorectal cancer (RAVELLO trial).. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, TPS789-TPS789	2.2	1
334	LUME-Colon 1: A double-blind, randomized phase III study of nintedanib plus best supportive care (BSC) versus placebo plus BSC in patients with colorectal cancer (CRC) refractory to standard therapies.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, TPS794-TPS794	2.2	2
333	Patterns of HER2 Gene Amplification and Response to Anti-HER2 Therapies. <i>PLoS ONE</i> , <b>2015</b> , 10, e0129876	2.2	28
332	Exploratory RAS analysis of the phase Ib/II 20060447 trial of rilotumumab (R) or ganitumab (G) plus panitumumab (pmab) versus pmab alone in patients (pts) with previously treated metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 694-694	2.2	
331	Clinical and molecular characterization of refractory BRAF mutant metastatic colorectal carcinoma (mCRC): Vall d'Hebron Institute of Oncology phase I program cohort.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 587-587	2.2	
330	Regional variation in physicians' awareness, understanding, and use of personalized medicine in the treatment of cancer and perception of patient (pt) education.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 574-574	2.2	
329	A multicenter phase II basket clinical trial of lurbinectedin (PM01183) in selected advanced solid tumors.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, TPS2604-TPS2604	2.2	
328	Measuring the impact of Next Generation Sequencing (NGS) technique implementation in metastatic colorectal cancer (mCRC) drug development program.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 3598-3598	2.2	
327	Comparison of three different molecular methods to detect mutations in KRAS, NRAS, BRAF and PIK3CA in metastatic colorectal cancer samples (mCRC): Interim analysis of a Spanish cohort.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, e14613-e14613	2.2	
326	Genomic landscape of anaplastic thyroid cancer.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 6033-6033	2.2	
325	Early drug development in advanced gynecologic cancer based on genetic tumor profiling.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 5562-5562	2.2	

324	Knocking on molecular alterations in advanced gastric cancer (AGC).. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 4063-4063	2.2	
323	Picking the point of inhibition: a comparative review of PI3K/AKT/mTOR pathway inhibitors. <i>Molecular Cancer Therapeutics</i> , <b>2014</b> , 13, 1021-31	6.1	324
322	Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer. <i>Annals of Oncology</i> , <b>2014</b> , 25, 1346-1355	10.3	353
321	Unmet needs and challenges in gastric cancer: the way forward. <i>Cancer Treatment Reviews</i> , <b>2014</b> , 40, 692-700	14.4	135
320	Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. <i>Lancet, The</i> , <b>2014</b> , 383, 31-39	40	1475
319	Circulating pEGFR is a candidate response biomarker of cetuximab therapy in colorectal cancer. <i>Clinical Cancer Research</i> , <b>2014</b> , 20, 6346-56	12.9	21
318	Guidelines for time-to-event end-point definitions in trials for pancreatic cancer. Results of the DATECAN initiative (Definition for the Assessment of Time-to-event End-points in CANcer trials). <i>European Journal of Cancer</i> , <b>2014</b> , 50, 2983-93	7.5	45
317	Epigenetic inactivation of the BRCA1 interactor SRBC and resistance to oxaliplatin in colorectal cancer. <i>Journal of the National Cancer Institute</i> , <b>2014</b> , 106, djt322	9.7	58
316	Enhancing the Biological Relevance of Secretome-Based Proteomics by Linking Tumor Cell Proliferation and Protein Secretion. <i>Journal of Proteome Research</i> , <b>2014</b> , 13, 3706-3721	5.6	6
315	Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial. <i>Lancet Oncology, The</i> , <b>2014</b> , 15, 862-73	21.7	190
314	Colon cancer-derived oncogenic EGFR G724S mutant identified by whole genome sequence analysis is dependent on asymmetric dimerization and sensitive to cetuximab. <i>Molecular Cancer</i> , <b>2014</b> , 13, 141	42.1	22
313	Cancer Core Europe: a consortium to address the cancer care-cancer research continuum challenge. <i>European Journal of Cancer</i> , <b>2014</b> , 50, 2745-6	7.5	20
312	First-in-human phase I study of Lurbinectedin (PM01183) in patients with advanced solid tumors. <i>Clinical Cancer Research</i> , <b>2014</b> , 20, 2205-14	12.9	54
311	TP53 mutational status and cetuximab benefit in rectal cancer: 5-year results of the EXPERT-C trial. <i>Journal of the National Cancer Institute</i> , <b>2014</b> , 106,	9.7	44
310	Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle. <i>Annals of Oncology</i> , <b>2014</b> , 25, 1729-1735	10.3	258
309	Prognosis and Therapeutic Implications for Emerging Colorectal Cancer Subtypes. <i>Current Colorectal Cancer Reports</i> , <b>2014</b> , 10, 55-61	1	4
308	TTD consensus document on the diagnosis and management of exocrine pancreatic cancer. <i>Clinical and Translational Oncology</i> , <b>2014</b> , 16, 865-78	3.6	5
307	Open-label, multicentre expansion cohort to evaluate imgatuzumab in pre-treated patients with KRAS-mutant advanced colorectal carcinoma. <i>European Journal of Cancer</i> , <b>2014</b> , 50, 496-505	7.5	24

306	SPROUTY2 is a Eatenin and FOXO3a target gene indicative of poor prognosis in colon cancer. <i>Oncogene</i> , <b>2014</b> , 33, 1975-85	9.2	21
305	PELO negatively regulates HER receptor signalling and metastasis. <i>Oncogene</i> , <b>2014</b> , 33, 1190-7	9.2	6
304	TGR analysis in phase I clinical trials--letter. <i>Clinical Cancer Research</i> , <b>2014</b> , 20, 2495-6	12.9	2
303	The evolution of our molecular understanding of colorectal cancer: what we are doing now, what the future holds, and how tumor profiling is just the beginning. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , <b>2014</b> , 91-9	7.1	24
302	Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors. <i>Annals of Oncology</i> , <b>2014</b> , 25, 552-563	10.3	242
301	A DERL3-associated defect in the degradation of SLC2A1 mediates the Warburg effect. <i>Nature Communications</i> , <b>2014</b> , 5, 3608	17.4	77
300	Evaluation of aflibercept in the treatment of metastatic colorectal cancer. <i>Expert Opinion on Biological Therapy</i> , <b>2014</b> , 14, 1493-505	5.4	9
299	A phase I/II, multiple-dose, dose-escalation study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with advanced solid tumors. <i>Clinical Cancer Research</i> , <b>2014</b> , 20, 2192-204	12.9	111
298	A catalyst for change: the European cancer Patient's Bill of Rights. <i>Oncologist</i> , <b>2014</b> , 19, 217-24	5.7	24
297	Unsupervised analyses reveal molecular subtypes associated to prognosis and response to therapy in colorectal cancer. <i>Colorectal Cancer</i> , <b>2014</b> , 3, 277-288	0.8	2
296	Paracrine network: another step in the complexity of resistance to EGFR blockade?. <i>Clinical Cancer Research</i> , <b>2014</b> , 20, 6227-9	12.9	4
295	Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors. <i>Annals of Oncology</i> , <b>2014</b> , 25, 2244-2251	10.3	133
294	Molecular features and survival outcomes of the intrinsic subtypes within HER2-positive breast cancer. <i>Journal of the National Cancer Institute</i> , <b>2014</b> , 106,	9.7	132
293	RHOA inactivation enhances Wnt signalling and promotes colorectal cancer. <i>Nature Communications</i> , <b>2014</b> , 5, 5458	17.4	85
292	Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset. <i>Annals of Oncology</i> , <b>2014</b> , 25, 2378-2385	10.3	72
291	Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245409 (XL765), a novel, orally administered PI3K/mTOR inhibitor in patients with advanced solid tumors. <i>Clinical Cancer Research</i> , <b>2014</b> , 20, 2445-56	12.9	76
290	Randomized phase Ib/II trial of rilotumumab or ganitumab with panitumumab versus panitumumab alone in patients with wild-type KRAS metastatic colorectal cancer. <i>Clinical Cancer Research</i> , <b>2014</b> , 20, 4240-50	12.9	83
289	An open-label phase II study evaluating the safety and efficacy of ramucirumab combined with mFOLFOX-6 as first-line therapy for metastatic colorectal cancer. <i>Oncologist</i> , <b>2014</b> , 19, 350-1	5.7	46

288	New approaches but the same flaws in the search for prognostic signatures. <i>Clinical Cancer Research</i> , <b>2014</b> , 20, 2019-22	12.9	3
287	Dose-response relationship in phase i clinical trials: a European Drug Development Network (EDDN) Collaboration Study. <i>Clinical Cancer Research</i> , <b>2014</b> , 20, 5663-71	12.9	11
286	A pharmacodynamic/pharmacokinetic study of ficlatuzumab in patients with advanced solid tumors and liver metastases. <i>Clinical Cancer Research</i> , <b>2014</b> , 20, 2793-804	12.9	29
285	Treatment-related mortality with aflibercept in cancer patients. <i>European Journal of Clinical Pharmacology</i> , <b>2014</b> , 70, 1269-70	2.8	1
284	Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial. <i>European Journal of Cancer</i> , <b>2014</b> , 50, 320-31	7.5	171
283	What could Nintedanib (BIBF 1120), a triple inhibitor of VEGFR, PDGFR, and FGFR, add to the current treatment options for patients with metastatic colorectal cancer?. <i>Critical Reviews in Oncology/Hematology</i> , <b>2014</b> , 92, 83-106	7	29
282	Colorectal cancer intrinsic subtypes predict chemotherapy benefit, deficient mismatch repair and epithelial-to-mesenchymal transition. <i>International Journal of Cancer</i> , <b>2014</b> , 134, 552-62	7.5	232
281	Abstract CT325: First in human study of JNJ-42756493, a potent pan fibroblast growth factor receptor (FGFR) inhibitor in patients with advanced solid tumors <b>2014</b> ,		15
280	Abstract CT326: Phase I study of BGJ398, a selective pan-FGFR inhibitor in genetically preselected advanced solid tumors <b>2014</b> ,		57
279	A phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 2500-2500	2.2	2
278	Phase 1 study of JNJ-42756493, a pan-fibroblast growth factor receptor (FGFR) inhibitor, in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 2501-2501	2.2	18
277	A phase 1 study of LJM716 in patients with esophageal squamous cell carcinoma, head and neck cancer, or HER2-overexpressing metastatic breast or gastric cancer.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 2517-2517	2.2	9
276	Phase I study of the selective BRAFV600 inhibitor encorafenib (LGX818) combined with cetuximab and with or without the $\pi$ -specific PI3K inhibitor BYL719 in patients with advanced BRAF-mutant colorectal cancer.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 3514-3514	2.2	14
275	Efficacy and tolerability in an open-label phase I/II study of MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in combination in patients (pts) with BRAF V600E mutated colorectal cancer (CRC).. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 3515-3515	2.2	31
274	VE-BASKET, a Simon 2-stage adaptive design, phase II, histology-independent study in nonmelanoma solid tumors harboring BRAF V600 mutations (V600m): Activity of vemurafenib (VEM) with or without cetuximab (CTX) in colorectal cancer (CRC).. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 3518-3518	2.2	17
273	Survival outcomes in patients (pts) with KRAS/NRAS (RAS) wild-type (WT) metastatic colorectal cancer (mCRC) and non-liver-limited disease (non-LLD): Data from the PRIME study.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 3550-3550	2.2	3
272	Panex: A pooled analysis of EXPERT and EXPERT-C, two trials of neoadjuvant chemotherapy (NACT) and chemoradiotherapy (CRT) in high-risk locally advanced rectal cancer (LARC).. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 3575-3575	2.2	5
271	REGARD: A phase 3, randomized, double-blind trial of ramucirumab (RAM) and best supportive care (BSC) versus placebo (PL) and BSC in the treatment of metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma following disease progression (PD) on first-line platinum- and/or fluoropyrimidine-containing combination therapy: Age subgroup analysis.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 4057-4057	2.2	3



270	First-in-human phase I Basket Study of Debio1347 (CH5183284), a novel FGFR inhibitor, in patients with FGFR genomically activated advanced solid tumors.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, TPS2629-TPS2629	2.2	2
269	A randomized phase II study (B2151005) of the intravenous phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) inhibitor PF-05212384 plus irinotecan versus cetuximab plus irinotecan in patients with wild-type KRAS metastatic colorectal cancer (mCRC)..	2.2	2
268	Updated survival from a randomized phase III trial (MPACT) of nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients (pts) with metastatic adenocarcinoma of the pancreas.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 178-178	2.2	12
267	Analysis of metabolic response (MR) by positron emission tomography (PET) compared with tumor response by computed tomography (CT) from MPACT, a phase III trial comparing nab-paclitaxel (nab-P) plus gemcitabine (G) versus G alone for patients (pts) with metastatic adenocarcinoma of the pancreas.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 351-351	2.2	3
266	RAS mutations in EXPERT-C, a randomized phase II trial of neoadjuvant capecitabine and oxaliplatin (CAPOX) and chemoradiotherapy (CRT) with or without cetuximab (C) in MRI-defined, high-risk rectal cancer (RC).. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 489-489	2.2	2
265	Molecular profiling in gynecologic cancer and matched targeted therapy: A step toward improving personalized medicine.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 5578-5578	2.2	1
264	Coexisting KRAS and PIK3CA exon 20 mutations as a potential poor-prognosis factor in metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 3591-3591	2.2	
263	Survival outcomes in the PRIME study for patients (pts) with RAS/BRAF wild-type (WT) metastatic colorectal cancer (mCRC), by baseline Eastern Cooperative Oncology Group (ECOG) performance status (PS).. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 3557-3557	2.2	
262	Incorporation of FGFR1 and FGFR2 amplification status determination in routine molecular prescreening for targeted therapies.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 11105-11105	2.2	
261	Prognostic value of KRAS exon 2 gene mutations in stage III colon cancer: Post hoc analyses of the PETACC8 trial.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 3549-3549	2.2	
260	Relationship of RAS and TP53 predictive value for cetuximab (C) benefit: Results of the EXPERT-C trial.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 447-447	2.2	
259	Phase I study of weekly kahalalide F as prolonged infusion in patients with advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2013</b> , 72, 75-83	3.5	24
258	A phase I pharmacokinetic study of PM00104 (Zalypsis) administered as a 24-h intravenous infusion every 3 weeks in patients with advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2013</b> , 71, 1247-54	3.5	8
257	Overview of biomarkers in metastatic colorectal cancer: tumour, blood and patient-related factors. <i>Critical Reviews in Oncology/Hematology</i> , <b>2013</b> , 85, 121-35	7	17
256	Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. <i>Lancet, The</i> , <b>2013</b> , 381, 303-12	4 <sup>0</sup>	1783
255	Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. <i>New England Journal of Medicine</i> , <b>2013</b> , 369, 1691-703	59.2	3788
254	The targeted therapy revolution in neuroendocrine tumors: in search of biomarkers for patient selection and response evaluation. <i>Cancer and Metastasis Reviews</i> , <b>2013</b> , 32, 465-77	9.6	8
253	Evaluation and clinical analyses of downstream targets of the Akt inhibitor GDC-0068. <i>Clinical Cancer Research</i> , <b>2013</b> , 19, 6976-86	12.9	63



252 Biomarker Discovery Strategies: DNA, RNA, and Protein **2013**, 401-416

251 Development of PI3K inhibitors: lessons learned from early clinical trials. *Nature Reviews Clinical Oncology*, **2013**, 10, 143-53 19.4 607

250 First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement. *Cancer Discovery*, **2013**, 3, 406-17 24.4 516

249 Molecular dissection of microsatellite instable colorectal cancer. *Cancer Discovery*, **2013**, 3, 502-11 24.4 68

248 A combined oncogenic pathway signature of BRAF, KRAS and PI3KCA mutation improves colorectal cancer classification and cetuximab treatment prediction. *Gut*, **2013**, 62, 540-9 19.2 107

247 Circulating tumour cells and cell-free DNA as tools for managing breast cancer. *Nature Reviews Clinical Oncology*, **2013**, 10, 377-89 19.4 146

246 Improving outcomes in colorectal cancer: where do we go from here?. *European Journal of Cancer*, **2013**, 49, 2476-85 7.5 34

245 Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. *New England Journal of Medicine*, **2013**, 369, 1023-34 59.2 1645

244 Phase II study of everolimus in patients with metastatic colorectal adenocarcinoma previously treated with bevacizumab-, fluoropyrimidine-, oxaliplatin-, and irinotecan-based regimens. *Clinical Cancer Research*, **2013**, 19, 3987-95 12.9 47

243 HER2 in high-risk rectal cancer patients treated in EXPERT-C, a randomized phase II trial of neoadjuvant capecitabine and oxaliplatin (CAPOX) and chemoradiotherapy (CRT) with or without cetuximab. *Annals of Oncology*, **2013**, 24, 3123-8 10.3 26

242 Efficacy and safety of bevacizumab in metastatic colorectal cancer: pooled analysis from seven randomized controlled trials. *Oncologist*, **2013**, 18, 1004-12 5.7 176

241 Biomarker-driven patient selection for early clinical trials. *Current Opinion in Oncology*, **2013**, 25, 305-12 4.2 30

240 Phase I pharmacokinetic and pharmacodynamic study of the first-in-class spliceosome inhibitor E7107 in patients with advanced solid tumors. *Clinical Cancer Research*, **2013**, 19, 6296-304 12.9 155

239 Constitutive HER2 signaling promotes breast cancer metastasis through cellular senescence. *Cancer Research*, **2013**, 73, 450-8 10.1 59

238 A randomized, placebo-controlled phase 2 study of ganitumab or conatumumab in combination with FOLFIRI for second-line treatment of mutant KRAS metastatic colorectal cancer. *Annals of Oncology*, **2013**, 24, 1777-1785 10.3 74

237 Cardiotoxicity **2013**, 483-530 1

236 Sorafenib in combination with oxaliplatin, leucovorin, and fluorouracil (modified FOLFOX6) as first-line treatment of metastatic colorectal cancer: the RESPECT trial. *Clinical Cancer Research*, **2013**, 19, 2541-50 12.9 61

235 A personalized preclinical model to evaluate the metastatic potential of patient-derived colon cancer initiating cells. *Clinical Cancer Research*, **2013**, 19, 6787-801 12.9 63

234	A randomized phase II study of PEP02 (MM-398), irinotecan or docetaxel as a second-line therapy in patients with locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma. <i>Annals of Oncology</i> , <b>2013</b> , 24, 1567-73	10.3	86
233	Mean overall survival gain with aflibercept plus FOLFIRI vs placebo plus FOLFIRI in patients with previously treated metastatic colorectal cancer. <i>British Journal of Cancer</i> , <b>2013</b> , 109, 1735-43	8.7	28
232	Genomic medicine frontier in human solid tumors: prospects and challenges. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 1874-84	2.2	90
231	Genomic analyses across six cancer types identify basal-like breast cancer as a unique molecular entity. <i>Scientific Reports</i> , <b>2013</b> , 3, 3544	4.9	42
230	Phase II open-label study to assess efficacy and safety of lenalidomide in combination with cetuximab in KRAS-mutant metastatic colorectal cancer. <i>PLoS ONE</i> , <b>2013</b> , 8, e62264	3.7	18
229	Impact of glucose-lowering agents on the risk of cancer in type 2 diabetic patients. The Barcelona case-control study. <i>PLoS ONE</i> , <b>2013</b> , 8, e79968	3.7	22
228	Immunomodulatory effects in a phase II study of lenalidomide combined with cetuximab in refractory KRAS-mutant metastatic colorectal cancer patients. <i>PLoS ONE</i> , <b>2013</b> , 8, e80437	3.7	24
227	Abstract C252: A phase 1, dose-escalation study of MLN0128, an investigational oral mammalian target of rapamycin complex 1/2 (mTORC1/2) catalytic inhibitor, in patients (pts) with advanced non-hematologic malignancies. <b>2013</b> ,		12
226	Abstract 3363: Pharmacodynamic (PD) assessment of drug activity in tumor tissue from patients (pts) enrolled in a Phase I study of MEHD7945A (MEHD), a first-in-class HER3/EGFR dual action antibody, in pts with locally advanced or metastatic epithelial tumors. <b>2013</b> ,		2
225	Phase Ib study evaluating safety and pharmacokinetics (PK) of the oral transforming growth factor-beta (TGF- $\beta$ ) receptor I kinase inhibitor LY2157299 monohydrate (LY) when combined with gemcitabine in patients with advanced cancer.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 2563-2563	2.2	3
224	Biomarkers and associations with the clinical activity of PD-L1 blockade in a MPDL3280A study.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 3001-3001	2.2	28
223	Analysis of KRAS/NRAS and BRAF mutations in the phase III PRIME study of panitumumab (pmab) plus FOLFOX versus FOLFOX as first-line treatment (tx) for metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 3511-3511	2.2	33
222	Analysis of plasma protein biomarkers from the CORRECT phase III study of regorafenib for metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 3514-3514	2.2	4
221	Effect of adding oxaliplatin to adjuvant 5-fluorouracil/leucovorin (5FU/LV) in patients with defective mismatch repair (dMMR) colon cancer stage II and III included in the MOSIAC study.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 3524-3524	2.2	16
220	Proof-of-concept study of Sym004, an anti-EGFR monoclonal antibody (mAb) mixture, in patients (pts) with anti-EGFR mab-refractory KRAS wild-type (wt) metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 3551-3551	2.2	5
219	Genomic classifier (ColoPrint) to predict outcome and chemotherapy benefit in stage II and III colon cancer patients.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 3612-3612	2.2	2
218	Overall survival (OS) analysis from PRIME: Randomized phase III study of panitumumab (pmab) with FOLFOX4 for first-line metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 3620-3620	2.2	6
217	Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic CRC, gastric cancer (GC), SCCHN, or other tumors.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 3622-3622	2.2	15

216	Results of a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas with PET and CA19-9 correlates.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 4005-4005	2.2	11
215	CA19-9 decrease at 8 weeks as a predictor of overall survival (OS) in a randomized phase III trial (MPACT) of weekly nab-paclitaxel (nab-P) plus gemcitabine (G) versus G alone in patients with metastatic pancreatic cancer (MPC).. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 4058-4058	2.2	2
214	Prognostic factors (PFs) of survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel (nab-P) plus gemcitabine (G) versus G alone in patients (pts) with metastatic pancreatic cancer (MPC).. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 4059-4059	2.2	3
213	ICE CREAM: Irinotecan cetuximab evaluation and the cetuximab response evaluation among patients with G13D mutation.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, TPS3649-TPS3649	2.2	2
212	Pertuzumab (P) with trastuzumab (T) and chemotherapy (CTX) in patients (pts) with HER2-positive metastatic gastric or gastroesophageal junction (GEJ) cancer: An international phase III study (JACOB).. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, TPS4150-TPS4150	2.2	10
211	MetGastric: A randomized phase III study of onartuzumab (MetMab) in combination with mFOLFOX6 in patients with metastatic HER2-negative and MET-positive adenocarcinoma of the stomach or gastroesophageal junction.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, TPS4155-TPS4155	2.2	12
210	POWER: An open-label, randomized phase III trial of cisplatin and 5-FU with or without panitumumab (P) for patients (pts) with nonresectable, advanced, or metastatic esophageal squamous cell cancer (ESCC).. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, TPS4158-TPS4158	2.2	1
209	Mutational analysis of biomarker samples from the CORRECT study: Correlating mutation status with clinical response to regorafenib.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 381-381	2.2	2
208	Analysis of overall survival and safety during the course of the phase III VELOUR trial comparing FOLFIRI and aflibercept or placebo in patients with mCRC that progressed on prior oxaliplatin treatment.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 451-451	2.2	2
207	Time course of regorafenib-associated adverse events in the phase III CORRECT study.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 467-467	2.2	14
206	On-treatment progression-free survival analysis of aflibercept-FOLFIRI treatment within 28 days of progression in metastatic colorectal cancer: Updated efficacy results from the VELOUR study.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 469-469	2.2	2
205	Phase II trial of miniDOX (reduced-dose docetaxel/oxaliplatin/capecitabine) in Euboptimal□ patients with advanced gastric cancer (AGC): TTD 08-02.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 87-87	2.2	1
204	Randomized phase III study of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic adenocarcinoma of the pancreas (MPACT).. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, LBA148-LBA148	2.2	34
203	REGARD: A phase III, randomized, double-blinded trial of ramucirumab and best supportive care (BSC) versus placebo and BSC in the treatment of metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma following disease progression on first-line platinum- and/or fluoropyrimidine containing combination therapy.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, LBA5-LBA5	2.2	10
202	Biomarkers for Go/No Go Decisions <b>2013</b> , 417-436		
201	Long-term efficacy and pharmacodynamic parameter analysis in pretreated KRAS-mutant metastatic colorectal carcinoma (mCRC) patients treated with RG7160 (GA201), an antibody-dependent cellular cytotoxicity (ADCC)-enhanced monoclonal anti-EGFR antibody.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 333-333	2.2	
200	Association of colorectal cancer intrinsic subtypes with prognosis, chemotherapy response, deficient mismatch repair, and epithelial to mesenchymal transition (EMT).. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 333-333	2.2	
199	Molecular characterization of nonpancreatic neuroendocrine neoplasms (NENS): First description of mutations in the tumor suppressor gene (TSG) SMARCB1 in NENS of colorectal origin using next-generation sequencing (NGS).. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 4135-4135	2.2	

198	Microarray gene expression study of the RESPECT trial for the identification of prognostic and predictive markers.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, e14561-e14561	2.2	
197	Molecular identification of basal-like breast cancer through genomic analyses across five cancer types.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 1011-1011	2.2	
196	Association of colorectal cancer intrinsic subtypes with prognosis, chemotherapy response, deficient mismatch repair, and epithelial to mesenchymal transition (EMT).. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 3530-3530	2.2	
195	Subgroup analyses results of the PETACC8 phase III trial comparing adjuvant FOLFOX4 with or without cetuximab (CTX) in resected stage III colon cancer (CC).. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 3525-3525	2.2	2
194	A phase I dose-escalating study of ES-285, a marine sphingolipid-derived compound, with repeat dose administration in patients with advanced solid tumors. <i>Investigational New Drugs</i> , <b>2012</b> , 30, 299-305	4.3	13
193	The oncosurgery approach to managing liver metastases from colorectal cancer: a multidisciplinary international consensus. <i>Oncologist</i> , <b>2012</b> , 17, 1225-39	5.7	352
192	Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors. <i>Annals of Oncology</i> , <b>2012</b> , 23, 2399-2408	10.3	112
191	First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study. <i>Oncologist</i> , <b>2012</b> , 17, 15-25	5.7	170
190	Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial. <i>Lancet Oncology, The</i> , <b>2012</b> , 13, 1225-33	21.7	389
189	ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making. <i>Annals of Oncology</i> , <b>2012</b> , 23, 2479-2516	10.3	984
188	Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 3499-506	2.2	1000
187	Ecaterin confers resistance to PI3K and AKT inhibitors and subverts FOXO3a to promote metastasis in colon cancer. <i>Nature Medicine</i> , <b>2012</b> , 18, 892-901	50.5	281
186	Multicenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with high-risk rectal cancer (EXPERT-C). <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 1620-7	2.2	293
185	Circulating tumour cells in early breast cancer. <i>Lancet Oncology, The</i> , <b>2012</b> , 13, e370; author reply e370	21.7	2
184	Neuroendocrine tumors: The age of targeted therapies. <i>Endocrinología Y Nutrición (English Edition)</i> , <b>2012</b> , 59, 438-451		
183	Recomendaciones para la determinación de mutaciones de K-RAS en cáncer de colon. <i>Revista Española De Patología</i> , <b>2012</b> , 45, 76-85	1.2	3
182	Drug development to overcome resistance to EGFR inhibitors in lung and colorectal cancer. <i>Molecular Oncology</i> , <b>2012</b> , 6, 15-26	7.9	62
181	Molecular profiling of patients with colorectal cancer and matched targeted therapy in phase I clinical trials. <i>Molecular Cancer Therapeutics</i> , <b>2012</b> , 11, 2062-71	6.1	66

180	A phase I study of sunitinib in combination with FOLFIRI in patients with untreated metastatic colorectal cancer. <i>Annals of Oncology</i> , <b>2012</b> , 23, 119-127	10.3	20
179	Patient selection for oncology phase I trials: a multi-institutional study of prognostic factors. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 996-1004	2.2	55
178	Sorafenib in metastatic thyroid cancer. <i>Endocrine-Related Cancer</i> , <b>2012</b> , 19, 209-16	5.7	86
177	Using pharmacokinetic and pharmacodynamic data in early decision making regarding drug development: a phase I clinical trial evaluating tyrosine kinase inhibitor, AEE788. <i>Clinical Cancer Research</i> , <b>2012</b> , 18, 6364-72	12.9	12
176	Molecular prescreening to select patient population in early clinical trials. <i>Nature Reviews Clinical Oncology</i> , <b>2012</b> , 9, 359-66	19.4	52
175	Panitumumab: a summary of clinical development in colorectal cancer and future directions. <i>Future Oncology</i> , <b>2012</b> , 8, 373-89	3.6	15
174	Application of monoclonal antibodies as cancer therapy in solid tumors. <i>Current Clinical Pharmacology</i> , <b>2012</b> , 7, 137-45	2.5	32
173	Phase I pharmacokinetic/pharmacodynamic study of MLN8237, an investigational, oral, selective aurora a kinase inhibitor, in patients with advanced solid tumors. <i>Clinical Cancer Research</i> , <b>2012</b> , 18, 4764-74	12.9	119
172	Adjuvant therapy with fluorouracil and oxaliplatin in stage II and elderly patients (between ages 70 and 75 years) with colon cancer: subgroup analyses of the Multicenter International Study of Oxaliplatin, Fluorouracil, and Leucovorin in the Adjuvant Treatment of Colon Cancer trial. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 3353-60	2.2	251
171	Genomic analysis identifies association of <i>Fusobacterium</i> with colorectal carcinoma. <i>Genome Research</i> , <b>2012</b> , 22, 292-8	9.7	1165
170	First-in-man phase I trial of two schedules of the novel synthetic tetrahydroisoquinoline alkaloid PM00104 (Zalypsis) in patients with advanced solid tumours. <i>British Journal of Cancer</i> , <b>2012</b> , 106, 1379-85	8.7	16
169	Brush border myosin Ia has tumor suppressor activity in the intestine. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2012</b> , 109, 1530-5	11.5	50
168	Gastrointestinal adenocarcinomas of the esophagus, stomach, and colon exhibit distinct patterns of genome instability and oncogenesis. <i>Cancer Research</i> , <b>2012</b> , 72, 4383-93	10.1	204
167	Trastuzumab-related cardiotoxicity in the elderly: a role for cardiovascular risk factors. <i>Annals of Oncology</i> , <b>2012</b> , 23, 897-902	10.3	107
166	Circulating tumor cell count is a prognostic factor in metastatic colorectal cancer patients receiving first-line chemotherapy plus bevacizumab: a Spanish Cooperative Group for the Treatment of Digestive Tumors study. <i>Oncologist</i> , <b>2012</b> , 17, 947-55	5.7	70
165	Dual mTORC1/2 and HER2 blockade results in antitumor activity in preclinical models of breast cancer resistant to anti-HER2 therapy. <i>Clinical Cancer Research</i> , <b>2012</b> , 18, 2603-12	12.9	137
164	Optimal use of EGFR inhibitors: challenges, new drugs and future directions <b>2012</b> , 72-81		
163	Abstract 5588: A phase I, open label, dose escalation study of an oral mammalian target of rapamycin inhibitor INK128 administered once daily in patients with advanced malignancies <b>2012</b> ,		8



162	Abstract CT-02: A phase I, open label, dose escalation study of oral mammalian target of rapamycin inhibitor INK128 administered by intermittent dosing regimens in patients with advanced malignancies <b>2012</b> ,		9
161	Abstract LB-122: A phase I dose escalation study of NVP-BGJ398, a selective pan FGFR inhibitor in genetically preselected advanced solid tumors <b>2012</b> ,		22
160	A phase I study of MEHD7945A (MEHD), a first-in-class HER3/EGFR dual-action antibody, in patients (pts) with refractory/recurrent epithelial tumors: Expansion cohorts.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 2568-2568	2.2	7
159	A phase Ib, open-label, multicenter, dose-escalation study of the oral pan-PI3K inhibitor BKM120 in combination with the oral MEK1/2 inhibitor GSK1120212 in patients (pts) with selected advanced solid tumors.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 3003-3003	2.2	14
158	A phase Ib study of the Akt inhibitor GDC-0068 with docetaxel (D) or mFOLFOX-6 (F) in patients (pts) with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 3021-3021	2.2	5
157	Open-label extension study of the RNAi therapeutic ALN-VSP02 in cancer patients responding to therapy.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 3062-3062	2.2	5
156	Phase III CORRECT trial of regorafenib in metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 3502-3502	2.2	15
155	Effects of prior bevacizumab (B) use on outcomes from the VELOUR study: A phase III study of aflibercept (Afl) and FOLFIRI in patients (pts) with metastatic colorectal cancer (mCRC) after failure of an oxaliplatin regimen.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 3505-3505	2.2	9
154	Validation of a genomic classifier (ColoPrint) for predicting outcome in the T3-MSS subgroup of stage II colon cancer patients.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 3510-3510	2.2	4
153	Molecular analysis of the randomized phase II/III study of the anti-IGF-1R antibody dalotuzumab (MK-0646) in combination with cetuximab (Cx) and irinotecan (Ir) in the treatment of chemorefractory KRAS wild-type metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 3531-3531	2.2	6
152	Phase I study of EMD 525797 (DI17E6), an antibody targeting $\alpha_5\beta_1$ Integrins, in combination with cetuximab and irinotecan, as a second-line treatment for patients with k-ras wild-type metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 3539-3539	2.2	1
151	Cetuximab combined with infusional 5-fluorouracil/folinic acid (5-FU/FA) and oxaliplatin in metastatic colorectal cancer (mCRC): A pooled analysis of COIN and OPUS study data.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 3574-3574	2.2	2
150	The role of TP, TS, and DPD as potential predictors of outcome following capecitabine plus oxaliplatin (XELOX) versus bolus 5-fluorouracil/leucovorin (5-FU/LV) as adjuvant therapy for stage III colon cancer: Biomarker findings from study NO16968 (XELOXA).. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 3578-3578	2.2	1
149	Meta-analysis of anti-VEGF class adverse events from three double-blind (db), placebo (pbo)-controlled phase III trials with IV aflibercept (Afl).. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 3579-3579	2.2	2
148	Activity of the anti-IGF-1R antibody dalotuzumab (MK-0646) in KRAS-mutant colorectal cancer: Preclinical and clinical data.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 3587-3587	2.2	2
147	International experts panel for the development of guidelines for the definition of time to event endpoints in clinical trials (DATECAN project): Results for pancreatic cancer.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 4053-4053	2.2	1
146	PI3K pathway (PI3Kp) dysregulation and response to pan-PI3K/AKT/mTOR/dual PI3K-mTOR inhibitors (PI3Kpi) in metastatic breast cancer (MBC) patients (pts).. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 509-509	2.2	3
145	A randomized, double-blind, phase (Ph) III study of the irinotecan-based chemotherapy FOLFIRI plus ramucirumab (RAM) or placebo (PL) in patients (pts) with metastatic colorectal carcinoma (mCRC) progressive during or following first-line therapy with bevacizumab (BEV), oxaliplatin (OXALI), and a fluoropyrimidine (FP) (RAISE) (NCT01103780).. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, TP53634-TP53634	2.2	2



144	The GAIN-C study (BP25438): Randomized phase II trial of RG7160 (GA201) plus FOLFIRI, compared to cetuximab plus FOLFIRI or FOLFIRI alone in second-line KRAS wild type (WT) or mutant metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, TPS3637-TPS3637	2.2	3
143	Clinical and technical validation of a genomic classifier (ColoPrint) for predicting outcome of patients with stage II colon cancer.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 384-384	2.2	7
142	Capecitabine plus oxaliplatin (XELOX) versus bolus 5-fluorouracil/leucovorin (5-FU/LV) as adjuvant therapy for stage III colon cancer: Survival follow-up of study NO16968 (XELOXA).. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 388-388	2.2	6
141	Final skin toxicity (ST) and patient-reported outcomes (PRO) results from PRIME: A randomized phase III study of panitumumab (pmab) plus FOLFOX4 (CT) for first-line metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 531-531	2.2	4
140	A phase II, open-label study evaluating the safety and efficacy of ramucirumab combined with mFOLFOX-6 as first-line therapy in patients (pts) with metastatic colorectal cancer (mCRC): CP12-0709/NCT00862784.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 533-533	2.2	10
139	Meta-analysis of anti-VEGF class adverse events from three double-blind (Db) placebo (Pbo)-controlled phase III trials with IV aflibercept (Afl).. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 561-561	2.2	9
138	New players in cancer therapeutics: Focus on inhibitors of Mdm2-p53 protein-protein interaction. <i>Drugs of the Future</i> , <b>2012</b> , 37, 273	2.3	3
137	Drug development in the era of personalized oncology: from population-based trials to enrichment and prescreening strategies. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , <b>2012</b> , 168-72	7.1	3
136	Presentation and treatment of HER2-positive metastatic breast cancer patients already treated with adjuvant trastuzumab.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 619-619	2.2	
135	Molecular profiling of patients (pts) with colorectal cancer (CRC) and matched targeted therapy (MTA) in phase I clinical trials.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 3014-3014	2.2	
134	Phase Ib study of CNTO 888 (anti-CCL 2) in combination with chemotherapies for treatment of patients with solid tumors.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 3059-3059	2.2	
133	Human pharmacokinetic (PK) characterization of the novel dual-action anti-HER3/EGFR antibody MEHD7945A (MEHD) in patients with refractory/recurrent epithelial tumors.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 2567-2567	2.2	1
132	Prognostic significance of PI3K pathway (PI3Kp) dysregulation in metastatic breast cancer (MBC) patients (pts).. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 566-566	2.2	
131	Abstract A19: A qPCR assay, OncoScore Colon, predicts resistance to cetuximab in formalin-fixed, paraffin-embedded colorectal cancer tissue independent of KRAS status. <i>Clinical Cancer Research</i> , <b>2012</b> , 18, A19-A19	12.9	
130	Analysis of the intratumoral heterogeneity of PIK3CA mutant alleles in breast cancer (BC): Implications for the luminal (LUM) phenotype.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 10511-10511	2.2	
129	Efficacy and safety of bevacizumab in metastatic colorectal cancer (mCRC): Pooled analysis from randomized controlled trials (RCTs).. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 3614-3614	2.2	
128	Amplification of fibroblast growth factor receptor type 1 gene (FGFR1) in samples from 101 NSCLC patients (pts) with squamous cell carcinoma (SCC) histology.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 7041-7041	2.2	
127	Genomic sequencing of colorectal adenocarcinomas identifies a recurrent VTI1A-TCF7L2 fusion. <i>Nature Genetics</i> , <b>2011</b> , 43, 964-968	36.3	242

126	Development of molecular biomarkers in individualized treatment of colorectal cancer. <i>Clinical Colorectal Cancer</i> , <b>2011</b> , 10, 279-89	3.8	22
125	Molecular predictors of response to chemotherapy in colorectal cancer. <i>Cancer Journal (Sudbury, Mass)</i> , <b>2011</b> , 17, 114-26	2.2	31
124	Prognostic and predictive roles for circulating biomarkers in gastrointestinal cancer. <i>Future Oncology</i> , <b>2011</b> , 7, 1385-97	3.6	33
123	Phase I pharmacokinetic and pharmacodynamic dose-escalation study of RG7160 (GA201), the first glycoengineered monoclonal antibody against the epidermal growth factor receptor, in patients with advanced solid tumors. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, 3783-90	2.2	70
122	Phase II trial of induction irinotecan-cisplatin followed by concurrent irinotecan-cisplatin and radiotherapy for unresectable, locally advanced gastric and oesophageal-gastric junction adenocarcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2011</b> , 67, 75-82	3.5	2
121	Feasibility of cetuximab given with a simplified schedule every 2 weeks in advanced colorectal cancer: a multicenter, retrospective analysis. <i>Medical Oncology</i> , <b>2011</b> , 28 Suppl 1, S253-8	3.7	14
120	Treatment recommendations for metastatic colorectal cancer. <i>Clinical and Translational Oncology</i> , <b>2011</b> , 13, 162-78	3.6	21
119	SEOM clinical guidelines for the treatment of pancreatic cancer. <i>Clinical and Translational Oncology</i> , <b>2011</b> , 13, 528-35	3.6	3
118	Pushing the envelope in the mTOR pathway: the second generation of inhibitors. <i>Molecular Cancer Therapeutics</i> , <b>2011</b> , 10, 395-403	6.1	117
117	Micromanaging the classification of colon cancer: the role of the microRNAome. <i>Clinical Cancer Research</i> , <b>2011</b> , 17, 7207-9	12.9	12
116	BRAF as a target for cancer therapy. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , <b>2011</b> , 11, 285-95	2.2	44
115	Toxicity as a biomarker of efficacy of molecular targeted therapies: focus on EGFR and VEGF inhibiting anticancer drugs. <i>Oncologist</i> , <b>2011</b> , 16, 1729-40	5.7	96
114	A phase I first-in-human pharmacokinetic and pharmacodynamic study of serdemetan in patients with advanced solid tumors. <i>Clinical Cancer Research</i> , <b>2011</b> , 17, 6313-21	12.9	49
113	A shining light in the darkness for the treatment of pancreatic neuroendocrine tumors. <i>Cancer Discovery</i> , <b>2011</b> , 1, 213-21	24.4	25
112	Control of carcinoid syndrome with everolimus. <i>Annals of Oncology</i> , <b>2011</b> , 22, 237-239	10.3	12
111	Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, 1465-71	2.2	526
110	A phase I pharmacokinetic and pharmacodynamic study of dalotuzumab (MK-0646), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in patients with advanced solid tumors. <i>Clinical Cancer Research</i> , <b>2011</b> , 17, 6304-12	12.9	102
109	Clinical activity of patupilone in patients with pretreated advanced/metastatic colon cancer: results of a phase I dose escalation trial. <i>British Journal of Cancer</i> , <b>2011</b> , 105, 1646-53	8.7	16

108	Phase I assessment of new mechanism-based pharmacodynamic biomarkers for MLN8054, a small-molecule inhibitor of Aurora A kinase. <i>Cancer Research</i> , <b>2011</b> , 71, 675-85	10.1	36
107	Abstract A167: First-in-patient study of PF-05212384, a small molecule intravenous dual inhibitor of PI3K and mTOR in patients with advanced cancer: Update on safety, efficacy, and pharmacology. <b>2011</b> ,		6
106	Abstract B154: A first-in-human trial of GDC-0068: A novel, oral, ATP-competitive Akt inhibitor, demonstrates robust suppression of the Akt pathway in surrogate and tumor tissues. <b>2011</b> ,		5
105	A Phase I Dose Expansion Cohort Study of the Safety, Pharmacokinetics and Pharmacodynamics of SAR245409 (S09), An Orally Administered PI3K/mTOR Inhibitor, in Patients with Lymphoma. <i>Blood</i> , <b>2011</b> , 118, 1608-1608	2.2	3
104	Recent developments in anti-cancer agents targeting PI3K, Akt and mTORC1/2. <i>Recent Patents on Anti-Cancer Drug Discovery</i> , <b>2011</b> , 6, 210-36	2.6	19
103	Drugs in clinical trials <b>2011</b> , 42-54		
102	The landscape of somatic copy-number alteration across human cancers. <i>Nature</i> , <b>2010</b> , 463, 899-905	50.4	2590
101	Cetuximab administered once every second week to patients with metastatic colorectal cancer: a two-part pharmacokinetic/pharmacodynamic phase I dose-escalation study. <i>Annals of Oncology</i> , <b>2010</b> , 21, 1537-1545	10.3	62
100	Toward efficient trials in colorectal cancer: the ARCAD Clinical Trials Program. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 527-30	2.2	18
99	Phase I study of the selective Aurora A kinase inhibitor MLN8054 in patients with advanced solid tumors: safety, pharmacokinetics, and pharmacodynamics. <i>Molecular Cancer Therapeutics</i> , <b>2010</b> , 9, 2844-52	6.1	73
98	Phase I safety, pharmacokinetics, and inhibition of SRC activity study of saracatinib in patients with solid tumors. <i>Clinical Cancer Research</i> , <b>2010</b> , 16, 4876-83	12.9	81
97	Toward optimized front-line therapeutic strategies in patients with metastatic colorectal cancer—an expert review from the International Congress on Anti-Cancer Treatment (ICACT) 2009. <i>Annals of Oncology</i> , <b>2010</b> , 21, 1579-1584	10.3	50
96	Analysis of the 10q11 cancer risk locus implicates MSMB and NCOA4 in human prostate tumorigenesis. <i>PLoS Genetics</i> , <b>2010</b> , 6, e1001204	6	70
95	Aprataxin tumor levels predict response of colorectal cancer patients to irinotecan-based treatment. <i>Clinical Cancer Research</i> , <b>2010</b> , 16, 2375-82	12.9	31
94	Cardiotoxicity. <i>Annals of Oncology</i> , <b>2010</b> , 21 Suppl 7, vii173-9	10.3	51
93	Multigene assays to improve assessment of recurrence risk and benefit from chemotherapy in early-stage colon cancer: has the time finally arrived, or are we still stage locked?. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 3904-7	2.2	8
92	Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 4697-705	2.2	1405
91	Pharmacogenomic and pharmacoproteomic studies of cetuximab in metastatic colorectal cancer: biomarker analysis of a phase I dose-escalation study. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 1181-9	2.2	99

90	Panitumumab - an effective long-term treatment for patients with metastatic colorectal cancer and wild-type KRAS status. <i>Cancer Treatment Reviews</i> , <b>2010</b> , 36 Suppl 1, S15-6	14.4	5
89	Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. <i>Lancet Oncology</i> , <b>2010</b> , 11, 753-62	21.7	1653
88	Status of PI3K inhibition and biomarker development in cancer therapeutics. <i>Annals of Oncology</i> , <b>2010</b> , 21, 683-691	10.3	121
87	EGFR and KRAS in colorectal cancer. <i>Advances in Clinical Chemistry</i> , <b>2010</b> , 51, 71-119	5.8	83
86	Integration of anti-epidermal growth factor receptor therapies with cytotoxic chemotherapy. <i>Cancer Journal (Sudbury, Mass)</i> , <b>2010</b> , 16, 226-34	2.2	5
85	Monoclonal antibodies in solid tumours. <i>Current Clinical Pharmacology</i> , <b>2010</b> , 5, 160-5	2.5	3
84	Biomarkers in colorectal cancer. <i>Clinical and Translational Oncology</i> , <b>2010</b> , 12, 261-70	3.6	1
83	Biomarkers for Therapies Directed at Angiogenesis. <i>Current Colorectal Cancer Reports</i> , <b>2010</b> , 6, 133-143	1	4
82	Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus. <i>Journal of Clinical Investigation</i> , <b>2010</b> , 120, 2858-66	15.9	282
81	Targeting the PI3K/Akt/mTOR Pathway - Beyond Rapalogs. <i>Oncotarget</i> , <b>2010</b> , 1, 530-543	3.3	255
80	Phase II randomized study of Plitidepsin (Aplidin), alone or in association with L-carnitine, in patients with unresectable advanced renal cell carcinoma. <i>Marine Drugs</i> , <b>2009</b> , 7, 57-70	6	31
79	The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 10th World Congress on Gastrointestinal Cancer, Barcelona, 2008. <i>Annals of Oncology</i> , <b>2009</b> , 20 Suppl 7, vii1-vii6	10.3	84
78	Changing the paradigm in conducting randomized clinical studies in advanced pancreatic cancer: an opportunity for better clinical development. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 5487-91	2.2	23
77	Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 3109-16	2.2	1568
76	New trends in epidermal growth factor receptor-directed monoclonal antibodies. <i>Immunotherapy</i> , <b>2009</b> , 1, 965-82	3.8	10
75	Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 3117-25	2.2	354
74	The role of salvage treatment in advanced colorectal cancer. <i>Critical Reviews in Oncology/Hematology</i> , <b>2009</b> , 71, 53-61	7	11
73	Consensus on the treatment of pancreatic cancer in Spain. <i>Clinical and Translational Oncology</i> , <b>2009</b> , 11, 290-301	3.6	4

72	Similarities and differences between the adjuvant oxaliplatin-based trials MOSAIC and NSABP C-07. <i>Current Colorectal Cancer Reports</i> , <b>2009</b> , 5, 166-170	1	
71	Targeted therapies in thyroid cancer. <i>Targeted Oncology</i> , <b>2009</b> , 4, 275-85	5	2
70	The 8q24 cancer risk variant rs6983267 shows long-range interaction with MYC in colorectal cancer. <i>Nature Genetics</i> , <b>2009</b> , 41, 882-4	36.3	550
69	Elderly patients with advanced colorectal cancer derive similar benefit without excessive toxicity after first-line chemotherapy with oxaliplatin-based combinations: comparative outcomes from the 03-TTD-01 phase III study. <i>Critical Reviews in Oncology/Hematology</i> , <b>2009</b> , 70, 134-44	7	42
68	Phase II trial of preoperative irinotecan-cisplatin followed by concurrent irinotecan-cisplatin and radiotherapy for resectable locally advanced gastric and esophagogastric junction adenocarcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2009</b> , 75, 1430-6	4	30
67	Anti-epidermal growth factor receptor monoclonal antibodies in cancer treatment. <i>Cancer Treatment Reviews</i> , <b>2009</b> , 35, 354-63	14.4	99
66	New approaches and targets in advanced colorectal cancer. <i>European Journal of Cancer</i> , <b>2009</b> , 45 Suppl 1, 79-88	7.5	4
65	Development of new drug strategies in infrequent digestive tumors: esophageal, biliary tract, and anal cancers. <i>Current Opinion in Oncology</i> , <b>2009</b> , 21, 374-80	4.2	3
64	Advances in targeted therapies for metastatic colorectal cancer. <i>Therapy: Open Access in Clinical Medicine</i> , <b>2009</b> , 6, 321-333		1
63	CDK8 is a colorectal cancer oncogene that regulates beta-catenin activity. <i>Nature</i> , <b>2008</b> , 455, 547-51	50.4	519
62	Microsatellite instability due to hMLH1 deficiency is associated with increased cytotoxicity to irinotecan in human colorectal cancer cell lines. <i>British Journal of Cancer</i> , <b>2008</b> , 99, 1607-12	8.7	70
61	Update on novel strategies to optimize cetuximab therapy in patients with metastatic colorectal cancer. <i>Clinical Colorectal Cancer</i> , <b>2008</b> , 7, 300-8	3.8	6
60	Understanding the predictive role of K-ras for epidermal growth factor receptor-targeted therapies in colorectal cancer. <i>Clinical Colorectal Cancer</i> , <b>2008</b> , 7 Suppl 2, S52-7	3.8	13
59	Pre-operative chemoradiotherapy with UFT and Leucovorin in patients with advanced rectal cancer: a phase II study. <i>Radiotherapy and Oncology</i> , <b>2008</b> , 89, 263-9	5.3	12
58	TGF-beta signalling-related markers in cancer patients with bone metastasis. <i>Biomarkers</i> , <b>2008</b> , 13, 217-36	36.6	50
57	The diagnosis and management of rectal cancer: expert discussion and recommendations derived from the 9th World Congress on Gastrointestinal Cancer, Barcelona, 2007. <i>Annals of Oncology</i> , <b>2008</b> , 19 Suppl 6, vi1-8	10.3	49
56	Potential regional differences for the tolerability profiles of fluoropyrimidines. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 2118-23	2.2	194
55	Phase I clinical and pharmacokinetic study of kahalalide F administered weekly as a 1-hour infusion to patients with advanced solid tumors. <i>Clinical Cancer Research</i> , <b>2008</b> , 14, 1116-23	12.9	47



54	Oxaliplatin-based chemotherapy in the management of colorectal cancer. <i>Expert Review of Anticancer Therapy</i> , <b>2008</b> , 8, 1223-36	3.5	32
53	Colorectal cancer metastasis resectability after treatment with the combination of oxaliplatin, irinotecan and 5-fluorouracil. Final results of a phase II study. <i>Acta Oncologica</i> , <b>2008</b> , 47, 286-92	3.2	11
52	Handling side-effects of targeted therapies: safety of targeted therapies in solid tumours. <i>Annals of Oncology</i> , <b>2008</b> , 19 Suppl 7, vii146-52	10.3	8
51	Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 1603-10	2.2	483
50	Administration of cetuximab every 2 weeks in the treatment of metastatic colorectal cancer: an effective, more convenient alternative to weekly administration?. <i>Oncologist</i> , <b>2008</b> , 13, 113-9	5.7	60
49	Phase I pharmacokinetic/pharmacodynamic study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor tyrosine kinase, in combination with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) in first-line treatment of patients with metastatic colorectal cancer. <i>Clinical Cancer Research</i> , <b>2008</b> , 14, 215-23	12.9	23
48	Cisplatin plus weekly CPT-11/docetaxel in advanced esophagogastric cancer: a phase I study with pharmacogenetic assessment of XPD, XRCC3 and UGT1A1 polymorphisms. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2008</b> , 62, 1075-83	3.5	13
47	Cetuximab efficacy and safety in a retrospective cohort of elderly patients with heavily pretreated metastatic colorectal cancer. <i>Critical Reviews in Oncology/Hematology</i> , <b>2008</b> , 67, 255-62	7	58
46	Aurora kinase family: a new target for anticancer drug. <i>Recent Patents on Anti-Cancer Drug Discovery</i> , <b>2008</b> , 3, 114-22	2.6	33
45	Aurora Kinases: A New Target for Anticancer Drug Development <b>2008</b> , 307-315		1
44	The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents. <i>Molecular Cancer Research</i> , <b>2007</b> , 5, 203-20	6.6	323
43	Phase II study of trabectedin in pretreated patients with advanced colorectal cancer. <i>Clinical Colorectal Cancer</i> , <b>2007</b> , 6, 522-8	3.8	13
42	Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer. <i>Journal of Clinical Oncology</i> , <b>2007</b> , 25, 5225-32	2.2	273
41	Chemotherapy and role of the proliferation marker Ki-67 in digestive neuroendocrine tumors. <i>Endocrine-Related Cancer</i> , <b>2007</b> , 14, 221-32	5.7	121
40	New approaches in systemic treatment of advanced colorectal cancer: the molecular targets era. <i>Expert Review of Anticancer Therapy</i> , <b>2007</b> , 7, 1027-41	3.5	2
39	Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients. <i>Journal of Clinical Oncology</i> , <b>2007</b> , 25, 102-9	2.2	196
38	Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer. <i>Journal of Clinical Oncology</i> , <b>2007</b> , 25, 3399-406	2.2	250
37	Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: final report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Trial. <i>Journal of Clinical Oncology</i> , <b>2007</b> , 25, 1224-30	2.2	219

36	Does chemotherapy prior to liver resection increase the potential for cure in patients with metastatic colorectal cancer? A report from the European Colorectal Metastases Treatment Group. <i>European Journal of Cancer</i> , <b>2007</b> , 43, 2037-45	7.5	203
35	Monoclonal antibodies in the treatment of advanced colorectal cancer. <i>European Journal of Surgical Oncology</i> , <b>2007</b> , 33 Suppl 2, S24-34	3.6	15
34	Reintroduction of oxaliplatin is associated with improved survival in advanced colorectal cancer. <i>Journal of Clinical Oncology</i> , <b>2007</b> , 25, 3224-9	2.2	107
33	Molecular biology of testicular germ cell tumors. <i>Clinical and Translational Oncology</i> , <b>2006</b> , 8, 846-50	3.6	5
32	Guides for adjuvant treatment of colon cancer. TTD Group (Spanish Cooperative Group for Gastrointestinal Tumor Therapy). <i>Clinical and Translational Oncology</i> , <b>2006</b> , 8, 98-102	3.6	5
31	Targeted therapies for patients with advanced colorectal cancer: focus on cetuximab. <i>Targeted Oncology</i> , <b>2006</b> , 1, 2-12	5	2
30	Emerging strategies in the treatment of advanced esophageal, gastroesophageal junction, and gastric cancer: the introduction of targeted therapies. <i>Targeted Oncology</i> , <b>2006</b> , 1, 23-33	5	1
29	Epidermal growth factor receptor (EGFR) inhibitors in gastrointestinal cancer. <i>Oncology Research and Treatment</i> , <b>2006</b> , 29, 99-105	2.8	4
28	Pharmacodynamic studies of gefitinib in tumor biopsy specimens from patients with advanced gastric carcinoma. <i>Journal of Clinical Oncology</i> , <b>2006</b> , 24, 4309-16	2.2	118
27	Novel targets for anticancer treatment development in colorectal cancer. <i>Clinical Colorectal Cancer</i> , <b>2006</b> , 6, 265-72	3.8	10
26	Current issues in adjuvant treatment of stage II colon cancer. <i>Annals of Surgical Oncology</i> , <b>2006</b> , 13, 887-98	3.8	81
25	Novel targets in gastric and esophageal cancer. <i>Critical Reviews in Oncology/Hematology</i> , <b>2006</b> , 59, 128-38	3.8	23
24	Efficacy and safety of tacrolimus compared with cyclosporin A microemulsion in renal transplantation: 2 year follow-up results. <i>Nephrology Dialysis Transplantation</i> , <b>2005</b> , 20, 968-73	4.3	101
23	Feasibility of CT scan-guided Tru-Cut serial liver biopsies to evaluate pharmacodynamic endpoints in patients with liver metastasis treated with experimental drugs. <i>Abdominal Imaging</i> , <b>2005</b> , 30, 65-8		2
22	Lack of efficacy of streptozocin and doxorubicin in patients with advanced pancreatic endocrine tumors. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , <b>2005</b> , 28, 424	2.7	1
21	The management of skin reactions in cancer patients receiving epidermal growth factor receptor targeted therapies. <i>JDDG - Journal of the German Society of Dermatology</i> , <b>2005</b> , 3, 599-606	1.2	94
20	Irreversible pan-ErbB tyrosine kinase inhibitor CI-1033 induces caspase-independent apoptosis in colorectal cancer DiFi cell line. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , <b>2005</b> , 10, 1175-86	5.4	12
19	Phase I pharmacokinetic and pharmacodynamic study of weekly 1-hour and 24-hour infusion BMS-214662, a farnesyltransferase inhibitor, in patients with advanced solid tumors. <i>Journal of Clinical Oncology</i> , <b>2005</b> , 23, 2521-33	2.2	25

18	Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer. <i>Journal of Clinical Oncology</i> , <b>2005</b> , 23, 5323-33	2.2	286
17	Novel targeted therapies in the treatment of gastric and esophageal cancer. <i>Annals of Oncology</i> , <b>2005</b> , 16, 1740-8	10.3	59
16	Targeted therapy in advanced colon cancer: the role of new therapies. <i>Annals of Oncology</i> , <b>2004</b> , 15 Suppl 4, iv55-62	10.3	26
15	XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. <i>Journal of Clinical Oncology</i> , <b>2004</b> , 22, 2084-91	2.2	421
14	A multicentre, randomised phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancer. <i>Annals of Oncology</i> , <b>2004</b> , 15, 1358-65	10.3	124
13	Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting. <i>Clinical Cancer Research</i> , <b>2004</b> , 10, 6487-501	12.9	257
12	Incidence of contralateral germ cell testicular tumors in South Europe: report of the experience at 2 Spanish university hospitals and review of the literature. <i>Journal of Urology</i> , <b>2004</b> , 171, 164-7	2.5	22
11	Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. <i>New England Journal of Medicine</i> , <b>2004</b> , 350, 2343-51	59.2	2728
10	Serial topoisomerase II expression in primary breast cancer and response to neoadjuvant anthracycline-based chemotherapy. <i>Oncology</i> , <b>2004</b> , 66, 388-94	3.6	43
9	New drugs and new approaches in metastatic bladder cancer. <i>Critical Reviews in Oncology/Hematology</i> , <b>2003</b> , 47, 195-206	7	25
8	Capecitabine (Xeloda) in combination with oxaliplatin: a phase I, dose-escalation study in patients with advanced or metastatic solid tumors. <i>Annals of Oncology</i> , <b>2002</b> , 13, 558-65	10.3	87
7	BOMP/EPI intensive alternating chemotherapy for IGCCC poor-prognosis germ-cell tumors: the Spanish Germ-Cell Cancer Group experience (GG). <i>Annals of Oncology</i> , <b>1999</b> , 10, 289-93	10.3	29
6	Phase II study of estramustine and vinorelbine in hormone-refractory prostate carcinoma patients. <i>Acta Oncologica</i> , <b>1998</b> , 37, 187-91	3.2	43
5	Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with weekly high-dose 48-hour continuous-infusion fluorouracil for advanced colorectal cancer: a Spanish Cooperative Group for Gastrointestinal Tumor Therapy (TTD) study. <i>Annals of Oncology</i> , <b>1998</b> , 9, 727-31	10.3	78
4	Mediastinal non-seminomatous germ cell tumours (MNSGCT) treated with cisplatin-based combination chemotherapy. <i>Annals of Oncology</i> , <b>1997</b> , 8, 555-9	10.3	28
3	A phase III randomized trial of cyclophosphamide, mitoxantrone, and 5-fluorouracil (CNF) versus cyclophosphamide, adriamycin, and 5-fluorouracil (CAF) in patients with metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , <b>1995</b> , 34, 15-24	4.4	24
2	Alpha-fetoprotein-concanavalin A binding as a marker to discriminate between germ cell tumours and liver diseases. <i>European Journal of Cancer</i> , <b>1995</b> , 31A, 2239-42	7.5	15
1	CHOP chemotherapy of intermediate and high-grade non-Hodgkin's lymphoma. <i>Acta Oncologica</i> , <b>1994</b> , 33, 935-9	3.2	4

